<SEC-DOCUMENT>0001731122-25-001626.txt : 20251203
<SEC-HEADER>0001731122-25-001626.hdr.sgml : 20251203
<ACCEPTANCE-DATETIME>20251202215313
ACCESSION NUMBER:		0001731122-25-001626
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251203
DATE AS OF CHANGE:		20251202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lunai Bioworks Inc.
		CENTRAL INDEX KEY:			0001527728
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				452259340
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-282898
		FILM NUMBER:		251544848

	BUSINESS ADDRESS:	
		STREET 1:		CENTURY CITY MEDICAL PLAZA
		STREET 2:		2080 CENTURY CITY EAST
		CITY:			SUITE 906 LOS ANGELES
		STATE:			CA
		ZIP:			90067
		BUSINESS PHONE:		45 39179840

	MAIL ADDRESS:	
		STREET 1:		CENTURY CITY MEDICAL PLAZA
		STREET 2:		2080 CENTURY CITY EAST
		CITY:			SUITE 906 LOS ANGELES
		STATE:			CA
		ZIP:			90067

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RENOVARO INC.
		DATE OF NAME CHANGE:	20240213

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RENOVARO BIOSCIENCES INC.
		DATE OF NAME CHANGE:	20230807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Enochian Biosciences Inc.
		DATE OF NAME CHANGE:	20230804
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>e7057_424b5.htm
<DESCRIPTION>FORM 424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>P<FONT STYLE="letter-spacing: -0.1pt">r</FONT>ospectus Supplement</B></FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: right; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed pursuant to Rule 424(b)(5)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(<FONT STYLE="letter-spacing: -0.8pt">T</FONT>o P<FONT STYLE="letter-spacing: -0.15pt">r</FONT>ospectus dated November 6, 2024)</B></FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration Statement No. 333-282898</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 52px; width: 147px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Lunai Bioworks Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Up to $11,702,826 of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.7pt">W</FONT>e
have entered into an ATM Sales Agreement (the &ldquo;Sal<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s
Agreement&rdquo;) wi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>h Dawson James Securit<FONT STYLE="letter-spacing: 0.05pt">i</FONT>es,
Inc. (&ldquo;Dawson James<FONT STYLE="letter-spacing: 0.05pt">&rdquo;</FONT>) r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>lating to
shares of our common stock, par value $0.0001 per share, (the &ldquo;<FONT STYLE="letter-spacing: 0.05pt">C</FONT>ommon Stock<FONT STYLE="letter-spacing: 0.05pt">&rdquo;</FONT>)
o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fered by this prospectus suppl<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ment <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd
the accompanying prospectus, filed as part of our regis<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ration stat<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ment
on Form S-3 (F<FONT STYLE="letter-spacing: 0.05pt">i</FONT>le No. 333-282898). In accordance with the <FONT STYLE="letter-spacing: 0.05pt">t</FONT>erms
of the Sa<FONT STYLE="letter-spacing: 0.05pt">l</FONT>es Agreement, under this prospectus supplement, we may o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fer
and sell shares of our Common Stock having an aggregate o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering pr<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ce
of up to $11,702,826 from time to time through Dawson James, acting <FONT STYLE="letter-spacing: 0.05pt">a</FONT>s our sales agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Sales of our Common Stock, if
an<FONT STYLE="letter-spacing: -0.55pt">y</FONT>, under this prospe<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tus supplement and the
accompanying prospectus will be made in sal<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s deemed <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o
be &ldquo;at the market o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>ferings&rdquo; <FONT STYLE="letter-spacing: 0.05pt">a</FONT>s defin<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d
in Rule 415(a)(4) promulgated under the Securities Act of 1933, <FONT STYLE="letter-spacing: 0.05pt">a</FONT>s am<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nded
(the &ldquo;S<FONT STYLE="letter-spacing: 0.05pt">e</FONT>curities Act&rdquo;), including sal<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s
made dir<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ctly on or through the Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) or any oth<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r
existing trading <FONT STYLE="letter-spacing: 0.05pt">m</FONT>arket in the Un<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ted Sta<FONT STYLE="letter-spacing: 0.05pt">t</FONT>es
for our Common S<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ock, sales made to or <FONT STYLE="letter-spacing: 0.05pt">t</FONT>hrough
a market maker oth<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r than on <FONT STYLE="letter-spacing: 0.05pt">a</FONT>n exchange or otherwise,
directly <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o Dawson Jam<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s as prin<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ipal,
in privately n<FONT STYLE="letter-spacing: 0.05pt">e</FONT>gotiated <FONT STYLE="letter-spacing: 0.05pt">t</FONT>ransactions, <FONT STYLE="letter-spacing: 0.05pt">i</FONT>n
block tr<FONT STYLE="letter-spacing: 0.05pt">a</FONT>des and/or <FONT STYLE="letter-spacing: 0.05pt">i</FONT>n any other method permitted
by la<FONT STYLE="letter-spacing: -0.5pt">w</FONT>. Dawson James is not required to sell any specific amount of Common Stock but will
use <FONT STYLE="letter-spacing: 0.05pt">i</FONT>ts comm<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rcially reasonable e<FONT STYLE="letter-spacing: -0.15pt">f</FONT>forts
consis<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ent w<FONT STYLE="letter-spacing: 0.05pt">i</FONT>th i<FONT STYLE="letter-spacing: 0.05pt">t</FONT>s
normal tr<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ding and sales pract<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ces and app<FONT STYLE="letter-spacing: 0.05pt">l</FONT>icable
laws and r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>gulations, subject to the terms of the Sal<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s
Agre<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ment, on mutu<FONT STYLE="letter-spacing: 0.05pt">a</FONT>lly agreed terms be<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ween
Dawson James and us. <FONT STYLE="letter-spacing: 0.05pt">T</FONT>here is no arrange<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ent for
funds to be re<FONT STYLE="letter-spacing: 0.05pt">c</FONT>eived in any es<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ro<FONT STYLE="letter-spacing: -0.55pt">w</FONT>,
trust or si<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ilar arrangem<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nt. See the se<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tion
entitled <FONT STYLE="letter-spacing: 0.05pt">&ldquo;</FONT><I>Plan of Distribution</I>&rdquo; for additional inform<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The compensation to Dawson James for sal<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s
of Co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>mon S<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ock sold pursu<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nt
to <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he Sales Agreement w<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ll be 3.0% of the gross
proce<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ds of any shares of Com<FONT STYLE="letter-spacing: 0.05pt">m</FONT>on Stock sold under
the Sales Agreement. In connection w<FONT STYLE="letter-spacing: 0.05pt">i</FONT>th the sa<FONT STYLE="letter-spacing: 0.05pt">l</FONT>e
of the Common Stock on our behalf, Dawson James will be dee<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ed to be an &ldquo;underwrit<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r&rdquo;
within the <FONT STYLE="letter-spacing: 0.05pt">m</FONT>eaning of the Se<FONT STYLE="letter-spacing: 0.05pt">c</FONT>urities Act and the
comp<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nsation of Dawson Jam<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s will be dee<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ed
to be underwriting commission or discount. <FONT STYLE="letter-spacing: -0.7pt">W</FONT>e have also agreed to provide indemnifi<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ation
and <FONT STYLE="letter-spacing: 0.05pt">c</FONT>ontribution to Dawson J<FONT STYLE="letter-spacing: 0.05pt">a</FONT>mes with respect
to certain liab<FONT STYLE="letter-spacing: 0.05pt">i</FONT>lities, including li<FONT STYLE="letter-spacing: 0.05pt">a</FONT>bilities
under the Securiti<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s Act or the Securities <FONT STYLE="letter-spacing: 0.05pt">E</FONT>xchange
Act of 1934, as amended (the &ldquo;Exch<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nge Act&rdquo;). This o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering
pursuant to this prospectus supplem<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nt and the accompanying prospectus w<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ll
terminate upon the earlier of (a) the sale of our <FONT STYLE="letter-spacing: 0.05pt">C</FONT>ommon S<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ock
pursuant to this prospectus supplement and the accompanying prospectus having an aggregate sa<FONT STYLE="letter-spacing: 0.05pt">l</FONT>es
price of $11,702,826, or (b) <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he terminat<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on by
us or Dawson Ja<FONT STYLE="letter-spacing: 0.05pt">m</FONT>es of <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he Sales Agree<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ent
pursuant to its ter<FONT STYLE="letter-spacing: 0.05pt">m</FONT>s. S<FONT STYLE="letter-spacing: 0.05pt">e</FONT>e the section entitled
<FONT STYLE="letter-spacing: 0.05pt">&ldquo;</FONT><I>Plan of Distribution</I>&rdquo; for additional inform<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tion
regarding Dawson Jam<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s<FONT STYLE="letter-spacing: 1.55pt">&rsquo;</FONT>compens<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.7pt">W</FONT>e
<FONT STYLE="letter-spacing: 0.05pt">a</FONT>re a &ldquo;small<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r reporting company&rdquo;
under <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he federal secur<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ties laws and, <FONT STYLE="letter-spacing: 0.05pt">a</FONT>s
such, are subject <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o reduced public co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>pany disclosure
standards for this prospec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>us supplement and fu<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ure
filings. See <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he sec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ion enti<FONT STYLE="letter-spacing: 0.05pt">t</FONT>led
&ldquo;<FONT STYLE="letter-spacing: 0.05pt"><I>P</I></FONT><I><FONT STYLE="letter-spacing: -0.3pt">r</FONT>ospectus Summary&mdash;Implications
of Be<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng a Smal<FONT STYLE="letter-spacing: 0.05pt">l</FONT>er Report<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng
Company</I>&rdquo; for additional inform<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus supplem<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nt,
the aggrega<FONT STYLE="letter-spacing: 0.05pt">t</FONT>e m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>rket v<FONT STYLE="letter-spacing: 0.05pt">a</FONT>lue
of our outstanding Common Stock h<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ld by non-a<FONT STYLE="letter-spacing: -0.1pt">f</FONT>filiates
is $35,108,479.50, based on <FONT STYLE="letter-spacing: 0.4pt">23,405,653 </FONT>shares of outstanding Common Stock he<FONT STYLE="letter-spacing: 0.05pt">l</FONT>d
by non-a<FONT STYLE="letter-spacing: -0.1pt">f</FONT>filiates as of <FONT STYLE="letter-spacing: 0.4pt">December 1, 2025</FONT> and a
price per share of $1.50, the c<FONT STYLE="letter-spacing: 0.05pt">l</FONT>osing price of our Co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>mon
S<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ock <FONT STYLE="letter-spacing: 0.05pt">a</FONT>s r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ported
on Nasd<FONT STYLE="letter-spacing: 0.05pt">a</FONT>q on November 19, 2025. Pursuant to General Instruct<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on
I.<FONT STYLE="letter-spacing: 0.05pt">B</FONT>.6 of Form S-3, in no <FONT STYLE="letter-spacing: 0.05pt">e</FONT>vent will we o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fer
to s<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ll, pursuant to the registrat<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on statement
of wh<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ch this prospectus suppl<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ment forms a part,
s<FONT STYLE="letter-spacing: 0.05pt">e</FONT>curities in a pub<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ic primary o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering
with a value exceed<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng on<FONT STYLE="letter-spacing: 0.05pt">e</FONT>-third of our public
flo<FONT STYLE="letter-spacing: 0.05pt">a</FONT>t in any 12-month period so long as the aggregate market value of our outst<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nding
Common Stock h<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ld by non-<FONT STYLE="letter-spacing: 0.05pt">a</FONT><FONT STYLE="letter-spacing: -0.15pt">f</FONT>filiates
r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>mains b<FONT STYLE="letter-spacing: 0.05pt">e</FONT>low $75 <FONT STYLE="letter-spacing: 0.05pt">m</FONT>illion.
During the pr<FONT STYLE="letter-spacing: 0.05pt">i</FONT>or 12-ca<FONT STYLE="letter-spacing: 0.05pt">l</FONT>enda<FONT STYLE="letter-spacing: -0.15pt">r</FONT>-month
period that ends on, and includes, the date of this prospectus supple<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ent, we have o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fered
no securi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ies pursuant to General Instruction I.B.6 of Form S-3. As a result, as of the date
of this prospectus, we are eligible to sell up to $11,702,826.50 of shares of our Common Stock under this prospectus, pursuant to General
Instruction I.B.6 of Form S-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Common Sto<FONT STYLE="letter-spacing: 0.05pt">c</FONT>k
is l<FONT STYLE="letter-spacing: 0.05pt">i</FONT>sted on the Nasdaq under the symbol &ldquo;LNAI&rdquo;. On <FONT STYLE="letter-spacing: 0.3pt">December
1, 2025</FONT>, the <FONT STYLE="letter-spacing: 0.05pt">l</FONT>ast reported sale pri<FONT STYLE="letter-spacing: 0.05pt">c</FONT>e of
our <FONT STYLE="letter-spacing: 0.05pt">C</FONT>ommon Stock on Nasdaq was $1.31 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Unless otherwise indicated,
the number of our shares of Common Stock presented in this prospectus supplement is adjusted to reflect the Reverse Stock Split that was
implemented on September 29, 2025. See the section entitled &ldquo;Prospectus Supplement Summary&mdash;Reverse Stock Split&rdquo; for
more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><B>Investing in our Common Stock
involves a high deg<FONT STYLE="letter-spacing: -0.05pt">r</FONT>ee of r<FONT STYLE="letter-spacing: 0.05pt">i</FONT>sk. S<FONT STYLE="letter-spacing: 0.05pt">e</FONT>e
the &ldquo;<I>Risk Factors</I>&ldquo; se<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tion b<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ginning
on page <FONT STYLE="letter-spacing: 1.45pt">S-7 </FONT>of this p<FONT STYLE="letter-spacing: -0.1pt">r</FONT>ospectus supplement and
page 5 of the ac<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ompanying p<FONT STYLE="letter-spacing: -0.1pt">r</FONT>ospectus, as well
as our other filings that a<FONT STYLE="letter-spacing: -0.1pt">r</FONT>e in<FONT STYLE="letter-spacing: 0.05pt">c</FONT>orporated by
<FONT STYLE="letter-spacing: -0.1pt">r</FONT>efe<FONT STYLE="letter-spacing: -0.15pt">r</FONT>ence <FONT STYLE="letter-spacing: 0.05pt">i</FONT>nto
this p<FONT STYLE="letter-spacing: -0.1pt">r</FONT>ospectus supplement and the accompanying p<FONT STYLE="letter-spacing: -0.1pt">r</FONT>ospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><B>Neither the <FONT STYLE="letter-spacing: 0.05pt">S</FONT>ecurities
and Exchange Commission (the &ldquo;SEC&rdquo;) nor any state secu<FONT STYLE="letter-spacing: 0.05pt">r</FONT>ities commission has app<FONT STYLE="letter-spacing: -0.15pt">r</FONT>oved
or disapp<FONT STYLE="letter-spacing: -0.1pt">r</FONT>oved of these securities or passed upon the adequacy or accuracy of this p<FONT STYLE="letter-spacing: -0.1pt">r</FONT>ospectus
supplement or the accompanying p<FONT STYLE="letter-spacing: -0.1pt">r</FONT>ospectus. Any <FONT STYLE="letter-spacing: -0.1pt">r</FONT>ep<FONT STYLE="letter-spacing: -0.15pt">r</FONT>esentation
to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Dawson James Securities, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">This
prospectus supplem<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nt is dated December 2, 2025</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 239.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 239.9pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 239.9pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="letter-spacing: -0.65pt"><B>T</B></FONT><B>ABLE
OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 239.9pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>PROSPECTUS SUPP<FONT STYLE="letter-spacing: 0.05pt">L</FONT>EMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS SUPPLEMENT</FONT></A></TD>
    <TD STYLE="text-align: right; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.5pt"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONA<FONT STYLE="letter-spacing: -0.45pt">R</FONT>Y NOTE REGARDING FO<FONT STYLE="letter-spacing: -0.45pt">R</FONT><FONT STYLE="letter-spacing: -1pt">W</FONT>ARD-LOOKING S<FONT STYLE="letter-spacing: -0.7pt">T</FONT><FONT STYLE="letter-spacing: -1pt">A</FONT>TEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-2</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUPPLEMENT SUMMA<FONT STYLE="letter-spacing: -0.45pt">R</FONT>Y</FONT></A></TD>
    <TD STYLE="text-align: right; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-3</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFERING</FONT></A></TD>
    <TD STYLE="text-align: right; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-7</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK <FONT STYLE="letter-spacing: -0.65pt">F</FONT>AC<FONT STYLE="letter-spacing: -0.15pt">T</FONT>ORS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -1.85pt">&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<FONT STYLE="letter-spacing: -0.35pt">13</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND POLICY</FONT></A></TD>
    <TD STYLE="text-align: right; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-14</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DILUTION</FONT></A></TD>
    <TD STYLE="text-align: right; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;S-15</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF SECURITIES W<FONT STYLE="letter-spacing: 1.7pt">E</FONT>ARE OFFERING</FONT></A></TD>
    <TD STYLE="text-align: right; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-16</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: right; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;S-17</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL M<FONT STYLE="letter-spacing: -1pt">A</FONT>TTERS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-19</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPE<FONT STYLE="letter-spacing: -0.5pt">R</FONT>TS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.4pt">&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-19</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORM<FONT STYLE="letter-spacing: -1pt">A</FONT>TION</FONT></A></TD>
    <TD STYLE="text-align: right; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-19</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPOR<FONT STYLE="letter-spacing: -0.95pt">A</FONT>TION OF CE<FONT STYLE="letter-spacing: -0.5pt">R</FONT><FONT STYLE="letter-spacing: -0.75pt">T</FONT>AIN INFORM<FONT STYLE="letter-spacing: -0.95pt">A</FONT>TION BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: right; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;S-20</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0pt; text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: left; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 258.15pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#y_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#y_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#y_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#y_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#y_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#y_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;6</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#y_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;7</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#y_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;8</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#y_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;9</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#y_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;12</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#y_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;12</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#y_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;12</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#y_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 258.15pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.95pt"><B>Y</B></FONT><B>ou
should <FONT STYLE="letter-spacing: -0.1pt">r</FONT>ely only on the informat<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on we have p<FONT STYLE="letter-spacing: -0.1pt">r</FONT>ovided
or incorporated by <FONT STYLE="letter-spacing: -0.1pt">r</FONT>efe<FONT STYLE="letter-spacing: -0.15pt">r</FONT>ence in this p<FONT STYLE="letter-spacing: -0.1pt">r</FONT>ospectus
suppl<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ment. <FONT STYLE="letter-spacing: -0.45pt">W</FONT>e have not authorized anyone to
p<FONT STYLE="letter-spacing: -0.1pt">r</FONT>ovide you with information diffe<FONT STYLE="letter-spacing: -0.1pt">r</FONT>ent f<FONT STYLE="letter-spacing: -0.15pt">r</FONT>om
that contained or incorporated by <FONT STYLE="letter-spacing: -0.15pt">r</FONT>efe<FONT STYLE="letter-spacing: -0.15pt">r</FONT>ence
in this p<FONT STYLE="letter-spacing: -0.1pt">r</FONT>ospectus supplement.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><B>This p<FONT STYLE="letter-spacing: -0.1pt">r</FONT>ospectus
supplement <FONT STYLE="letter-spacing: 0.05pt">i</FONT>s an offer to sell only the <FONT STYLE="letter-spacing: 0.05pt">s</FONT>ecurities
offe<FONT STYLE="letter-spacing: -0.1pt">r</FONT>ed he<FONT STYLE="letter-spacing: -0.1pt">r</FONT>eb<FONT STYLE="letter-spacing: -0.5pt">y</FONT>,
but only und<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r ci<FONT STYLE="letter-spacing: -0.1pt">r</FONT>cumstances and in ju<FONT STYLE="letter-spacing: 0.05pt">r</FONT>isdictions
wh<FONT STYLE="letter-spacing: 0.05pt">e</FONT><FONT STYLE="letter-spacing: -0.15pt">r</FONT>e it <FONT STYLE="letter-spacing: 0.05pt">i</FONT>s
lawful to do so.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><B><FONT STYLE="letter-spacing: -0.95pt">Y</FONT>ou shou<FONT STYLE="letter-spacing: 0.05pt">l</FONT>d assume that the information
conta<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ned in this p<FONT STYLE="letter-spacing: -0.15pt">r</FONT>ospectus supplement is accurate
only as of their <FONT STYLE="letter-spacing: -0.1pt">r</FONT>espective dates and that any information we have incorporat<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d
by <FONT STYLE="letter-spacing: -0.1pt">r</FONT>efe<FONT STYLE="letter-spacing: -0.15pt">r</FONT>ence is accurate only as of the date
of the document incorporated by <FONT STYLE="letter-spacing: -0.1pt">r</FONT>efe<FONT STYLE="letter-spacing: -0.1pt">r</FONT>ence, <FONT STYLE="letter-spacing: -0.15pt">r</FONT>egardless
of the time of delivery of this p<FONT STYLE="letter-spacing: -0.1pt">r</FONT>ospective supplement for any sale of securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS SUP<FONT STYLE="letter-spacing: 0.05pt">P</FONT>LEMENT</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 197.45pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">This docum<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nt
conta<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ns two parts. The first part is this prospe<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tus
supplem<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nt, which describes the sp<FONT STYLE="letter-spacing: 0.05pt">e</FONT>cific terms
of this o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering and <FONT STYLE="letter-spacing: 0.05pt">a</FONT>lso supplements and updates
informa<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ion contained in the a<FONT STYLE="letter-spacing: 0.05pt">c</FONT>companying prospectus
and the docum<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nts incorporated by reference <FONT STYLE="letter-spacing: 0.05pt">i</FONT>nto
this prospe<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tus supplement and <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ccompanying
prospectus. The second part is the accompanying prospectus, which provides more general infor<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ation,
some of whi<FONT STYLE="letter-spacing: 0.05pt">c</FONT>h does not apply to this o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering.
If the information <FONT STYLE="letter-spacing: 0.05pt">c</FONT>ontained in this prospec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>us
supplement di<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fers or varies from <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he information
cont<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ined in the acco<FONT STYLE="letter-spacing: 0.05pt">m</FONT>panying prospectus, you
should rely on the information s<FONT STYLE="letter-spacing: 0.05pt">e</FONT>t forth in this prospectus suppl<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">This prospectus suppl<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ment
is part of a registra<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ion statem<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nt that we or<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ginally
fil<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d with the Se<FONT STYLE="letter-spacing: 0.05pt">c</FONT>urities and <FONT STYLE="letter-spacing: 0.05pt">E</FONT>xchange
Commiss<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on (the &ldquo;SEC<FONT STYLE="letter-spacing: 0.05pt">&rdquo;</FONT>) utilizing a
&ldquo;shelf&rdquo; registrat<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on process on October 30, 2024 and dec<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ared
e<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fective by the SEC on November 6, 2024. Und<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r
the she<FONT STYLE="letter-spacing: 0.05pt">l</FONT>f registra<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ion process, from time to ti<FONT STYLE="letter-spacing: 0.05pt">m</FONT>e,
we may o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fer and sell any of <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he securities d<FONT STYLE="letter-spacing: 0.05pt">e</FONT>scribed
in the a<FONT STYLE="letter-spacing: 0.05pt">c</FONT>companying prospectus separ<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tely or together
w<FONT STYLE="letter-spacing: 0.05pt">i</FONT>th other securiti<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s described therein.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.85pt">Y</FONT>ou
should rely only on the informa<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ion contain<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d
or incorporated by reference <FONT STYLE="letter-spacing: 0.05pt">i</FONT>n this prospec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>us
supplement and the a<FONT STYLE="letter-spacing: 0.05pt">c</FONT>companying prospectus. Neither we nor Dawson <FONT STYLE="letter-spacing: 0.05pt">J</FONT>ames
h<FONT STYLE="letter-spacing: 0.05pt">a</FONT>s author<FONT STYLE="letter-spacing: 0.05pt">i</FONT>zed anyone else to provide you with
information that is in <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ddition <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o or di<FONT STYLE="letter-spacing: -0.1pt">f</FONT>ferent
from that conta<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ned or incorporated by reference in this prospectus suppl<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ment
and the ac<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ompanying prospec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>us, along wi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>h
the <FONT STYLE="letter-spacing: 0.05pt">i</FONT>nformation con<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ained in any permi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ted
free writing prospe<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tuses we have authorized for use <FONT STYLE="letter-spacing: 0.05pt">i</FONT>n
connection with th<FONT STYLE="letter-spacing: 0.05pt">i</FONT>s o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fering.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.7pt">W</FONT>e
are o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering to sell, and seeking o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fers to bu<FONT STYLE="letter-spacing: -0.55pt">y</FONT>,
shares of our Common Stock only in jurisdic<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ions where o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fers
and sa<FONT STYLE="letter-spacing: 0.05pt">l</FONT>es are perm<FONT STYLE="letter-spacing: 0.05pt">i</FONT>tted. The information cont<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ined
in th<FONT STYLE="letter-spacing: 0.05pt">i</FONT>s prospectus supple<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ent and the accompanying
prosp<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ctus is a<FONT STYLE="letter-spacing: 0.05pt">c</FONT>curate only as of the d<FONT STYLE="letter-spacing: 0.05pt">a</FONT>te
of this prospectus supplem<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nt or the d<FONT STYLE="letter-spacing: 0.05pt">a</FONT>te of the
accompany<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng prospectus, as appli<FONT STYLE="letter-spacing: 0.05pt">c</FONT>able, and the
<FONT STYLE="letter-spacing: 0.05pt">i</FONT>nformation in the documents incorpora<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ed by reference
in this prospectus supple<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ent and the accompanying prospec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>us
is accura<FONT STYLE="letter-spacing: 0.05pt">t</FONT>e only as of the date of those respective do<FONT STYLE="letter-spacing: 0.05pt">c</FONT>uments,
regardless of the time of delivery of th<FONT STYLE="letter-spacing: 0.05pt">i</FONT>s prospectus supplem<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nt
and the accompanying prospe<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tus or of any s<FONT STYLE="letter-spacing: 0.05pt">a</FONT>le
of our Com<FONT STYLE="letter-spacing: 0.05pt">m</FONT>on Stock. Our business, financial condition, results of operations <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd
prospects may have changed s<FONT STYLE="letter-spacing: 0.05pt">i</FONT>nce those da<FONT STYLE="letter-spacing: 0.05pt">t</FONT>es.
It is important for you to r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ad and consider all information contain<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d
or incorporated by refer<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nce in this prospectus supplement and <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he
accompanying prospe<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tus in m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>king your invest<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ent
decis<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on. <FONT STYLE="letter-spacing: -0.85pt">Y</FONT>ou should read both <FONT STYLE="letter-spacing: 0.05pt">t</FONT>his
prospectus supplement <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd the a<FONT STYLE="letter-spacing: 0.05pt">c</FONT>companying prospectus,
as well as the documents in<FONT STYLE="letter-spacing: 0.05pt">c</FONT>orporated by reference into this prospec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>us
supplement and <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he accompany<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng prospectus and
the <FONT STYLE="letter-spacing: 0.05pt">a</FONT>dditional inform<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tion described under &ldquo;<I>Whe<FONT STYLE="letter-spacing: -0.3pt">r</FONT>e
<FONT STYLE="letter-spacing: -0.75pt">Y</FONT>ou Can Find Mo<FONT STYLE="letter-spacing: -0.25pt">r</FONT>e Information</I>&rdquo; and
&ldquo;<I>Incorporation of Documen<FONT STYLE="letter-spacing: 0.05pt">t</FONT>s by Refe<FONT STYLE="letter-spacing: -0.25pt">r</FONT>ence</I>&rdquo;
in this prospectus supple<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ent and in the accompanying prospe<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tus,
before investing in our Com<FONT STYLE="letter-spacing: 0.05pt">m</FONT>on Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.7pt">W</FONT>e
further note th<FONT STYLE="letter-spacing: 0.05pt">a</FONT>t the represent<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tions, warran<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ies
<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd covenants made by us in <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ny agreem<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nt
that is filed as an exhibit to <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ny document that is incorporated by ref<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rence
in <FONT STYLE="letter-spacing: 0.05pt">t</FONT>his prospe<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tus suppl<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ment
or the ac<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ompanying prospectus were <FONT STYLE="letter-spacing: 0.05pt">m</FONT>ade solely
for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating r<FONT STYLE="letter-spacing: 0.05pt">i</FONT>sk
among the par<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ies to such agre<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ments. Moreove<FONT STYLE="letter-spacing: -0.3pt">r</FONT>,
such repres<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ntations, warran<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ies or covenants
w<FONT STYLE="letter-spacing: 0.05pt">e</FONT>re accurate on<FONT STYLE="letter-spacing: 0.05pt">l</FONT>y as of the date wh<FONT STYLE="letter-spacing: 0.05pt">e</FONT>n
made. Ac<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ordingl<FONT STYLE="letter-spacing: -0.55pt">y</FONT>, such representations, warranties
<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd covenants shou<FONT STYLE="letter-spacing: 0.05pt">l</FONT>d not be re<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ied
on as accurate<FONT STYLE="letter-spacing: 0.05pt">l</FONT>y representing <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he current state
of our a<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Unless otherwise st<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ted,
all ref<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rences to &ldquo;us,&rdquo; <FONT STYLE="letter-spacing: 0.05pt">&ldquo;</FONT>ou<FONT STYLE="letter-spacing: -0.35pt">r</FONT>,&rdquo;
<FONT STYLE="letter-spacing: 0.05pt">&ldquo;</FONT>we,&rdquo; the &ldquo;Co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>pany&rdquo; and
simil<FONT STYLE="letter-spacing: 0.05pt">a</FONT>r designations refer <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o Lunai Bioworks Inc.
and <FONT STYLE="letter-spacing: 0.05pt">i</FONT>ts consolidated subsidiaries. Our <FONT STYLE="letter-spacing: 0.05pt">l</FONT>ogo, tr<FONT STYLE="letter-spacing: 0.05pt">a</FONT>demarks
and serv<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ce marks <FONT STYLE="letter-spacing: 0.05pt">a</FONT>re <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he
proper<FONT STYLE="letter-spacing: 0.05pt">t</FONT>y of Lunai Bioworks Inc. and its consolidated subsidi<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ries.
O<FONT STYLE="letter-spacing: 0.05pt">t</FONT>her <FONT STYLE="letter-spacing: 0.05pt">t</FONT>rademarks or s<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rvice
marks appearing in this prospec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>us supplement are <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he
property of their respec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ive holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>




<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><A NAME="a_002"></A>CAUTIONA<FONT STYLE="letter-spacing: -0.3pt">R</FONT>Y NOTE
REGARDING FO<FONT STYLE="letter-spacing: -0.3pt">R</FONT><FONT STYLE="letter-spacing: -1pt">W</FONT>ARD-LOOKING S<FONT STYLE="letter-spacing: -0.6pt">T</FONT><FONT STYLE="letter-spacing: -0.7pt">A</FONT>TEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 135.3pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">This prospectus supplement, the <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ccompanying
prospectus, and the docum<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nts incorporated by reference her<FONT STYLE="letter-spacing: 0.05pt">e</FONT>in
contain forward-looking stat<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ments that r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>flect
our current expecta<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ions and views of future events. The forward-looking statemen<FONT STYLE="letter-spacing: 0.05pt">t</FONT>s
are contained principal<FONT STYLE="letter-spacing: 0.05pt">l</FONT>y in the s<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ctions <FONT STYLE="letter-spacing: 0.05pt">i</FONT>ncluded
or incorporated by referen<FONT STYLE="letter-spacing: 0.05pt">c</FONT>e here<FONT STYLE="letter-spacing: 0.05pt">i</FONT>n enti<FONT STYLE="letter-spacing: 0.05pt">t</FONT>led
<FONT STYLE="letter-spacing: 0.05pt">&ldquo;</FONT><I>Risk Factors</I>&rdquo; and <FONT STYLE="letter-spacing: 0.05pt">&ldquo;</FONT>M<I>anagement<FONT STYLE="letter-spacing: -1.1pt">&rsquo;</FONT>s
Discuss<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on and Anal<FONT STYLE="letter-spacing: 0.05pt">y</FONT>sis of Financial Condit<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on
and <FONT STYLE="letter-spacing: 0.05pt">R</FONT>esults of Operat<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ons</I>.&rdquo; Readers
are <FONT STYLE="letter-spacing: 0.05pt">c</FONT>autioned <FONT STYLE="letter-spacing: 0.05pt">t</FONT>hat known and unknown risks, uncertainti<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s
and other factors, <FONT STYLE="letter-spacing: 0.05pt">i</FONT>ncluding <FONT STYLE="letter-spacing: 0.05pt">t</FONT>hose over which
we m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>y have no con<FONT STYLE="letter-spacing: 0.05pt">t</FONT>rol and others listed in the
&ldquo;<I>Risk Fa<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tors</I>&rdquo; section of this prospe<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tus
supplement, may <FONT STYLE="letter-spacing: 0.05pt">c</FONT>ause our actual resul<FONT STYLE="letter-spacing: 0.05pt">t</FONT>s, p<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rformance
or achiev<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ments to be mater<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ally di<FONT STYLE="letter-spacing: -0.1pt">f</FONT>ferent
from those expressed or implied by the forward-looking statem<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nts.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">These forward-<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ooking
stat<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ments <FONT STYLE="letter-spacing: 0.05pt">i</FONT>nvolve numerous risks <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd
uncerta<FONT STYLE="letter-spacing: 0.05pt">i</FONT>nties. A<FONT STYLE="letter-spacing: 0.05pt">l</FONT>though we believe that our expect<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tions
expr<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ssed in these forward-looking statements are r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>asonable,
our expectat<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ons <FONT STYLE="letter-spacing: 0.05pt">m</FONT>ay later be found to be incorrect.
Our actual r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>sults of operations or the results of other mat<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ers
<FONT STYLE="letter-spacing: 0.05pt">t</FONT>hat we anticipate could be mat<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rially di<FONT STYLE="letter-spacing: -0.15pt">f</FONT>ferent
from our expec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ations. Import<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nt risks and fac<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ors
that could <FONT STYLE="letter-spacing: 0.05pt">c</FONT>ause our actual results <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o be <FONT STYLE="letter-spacing: 0.05pt">m</FONT>aterial<FONT STYLE="letter-spacing: 0.05pt">l</FONT>y
di<FONT STYLE="letter-spacing: -0.1pt">f</FONT>ferent from our expectations are generally set forth <FONT STYLE="letter-spacing: 0.05pt">i</FONT>n
&ldquo;<I>Risk Factor<FONT STYLE="letter-spacing: 0.05pt">s</FONT></I>,&rdquo; &ldquo;<I>Management<FONT STYLE="letter-spacing: -1.1pt">&rsquo;</FONT>s
Discussion and Analys<FONT STYLE="letter-spacing: 0.05pt">i</FONT>s of Financial Condi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ion
and <FONT STYLE="letter-spacing: 0.05pt">R</FONT>esults of Operation<FONT STYLE="letter-spacing: 0.05pt">s</FONT></I>,&rdquo; &ldquo;<I>Business</I>,&rdquo;
and other sections included or in<FONT STYLE="letter-spacing: 0.05pt">c</FONT>orporated by reference in this prospe<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tus
supple<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ent. <FONT STYLE="letter-spacing: -0.85pt">Y</FONT>ou should thoroughly read this prospectus
supplement and the documents <FONT STYLE="letter-spacing: 0.05pt">i</FONT>ncorporated her<FONT STYLE="letter-spacing: 0.05pt">e</FONT>in
by r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ference <FONT STYLE="letter-spacing: 0.05pt">w</FONT>ith the understanding that our actual
future results m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>y be material<FONT STYLE="letter-spacing: 0.05pt">l</FONT>y di<FONT STYLE="letter-spacing: -0.1pt">f</FONT>ferent
from and worse than what we expect. <FONT STYLE="letter-spacing: -0.75pt">W</FONT>e qualify all of our forward-looking st<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tements
by these cautionary sta<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ements.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">The forward-looking s<FONT STYLE="letter-spacing: 0.05pt">t</FONT>atements
made in <FONT STYLE="letter-spacing: 0.05pt">t</FONT>his prospectus supp<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ement rel<FONT STYLE="letter-spacing: 0.05pt">a</FONT>te
only <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o events or <FONT STYLE="letter-spacing: 0.05pt">i</FONT>nformation as of the da<FONT STYLE="letter-spacing: 0.05pt">t</FONT>e
on which <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he state<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ents are made in or incorpora<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ed
by referen<FONT STYLE="letter-spacing: 0.05pt">c</FONT>e in this prospectus supple<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ent. <FONT STYLE="letter-spacing: 0.05pt">E</FONT>xcept
as required by l<FONT STYLE="letter-spacing: 0.05pt">a</FONT><FONT STYLE="letter-spacing: -0.55pt">w</FONT>, we under<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ake
no oblig<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tion <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o upda<FONT STYLE="letter-spacing: 0.05pt">t</FONT>e
or revise publi<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ly any forward-looking s<FONT STYLE="letter-spacing: 0.05pt">t</FONT>atements,
whether as a result of new informa<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ion, future ev<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nts
or otherwise, aft<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r the date on which the statemen<FONT STYLE="letter-spacing: 0.05pt">t</FONT>s
are made or to reflect the occurrence of unanticipa<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ed events. <FONT STYLE="letter-spacing: -0.9pt">Y</FONT>ou
should read this prospectus supple<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ent, the documents incorporat<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d
by refer<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nce into this prospectus supplement <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd
the documents we have filed <FONT STYLE="letter-spacing: 0.05pt">a</FONT>s exhibits to the registration statemen<FONT STYLE="letter-spacing: 0.05pt">t</FONT>,
of which this prospec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>us supplement forms a p<FONT STYLE="letter-spacing: 0.05pt">a</FONT>rt,
comple<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ely and with the understanding that our actual fu<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ure
results may be m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>terially di<FONT STYLE="letter-spacing: -0.1pt">f</FONT>ferent from what
we expect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B><A NAME="a_003"></A>PROSPECTUS SUPP<FONT STYLE="letter-spacing: 0.05pt">L</FONT>EMENT
SUMMA<FONT STYLE="letter-spacing: -0.3pt">R</FONT>Y</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 201.4pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><I>This summary highl<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ghts
certain information about us, this offer<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng and selec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ed
information contained el<FONT STYLE="letter-spacing: 0.05pt">s</FONT>ewhe<FONT STYLE="letter-spacing: -0.3pt">r</FONT>e or incorporated
by <FONT STYLE="letter-spacing: -0.3pt">r</FONT>efe<FONT STYLE="letter-spacing: -0.3pt">r</FONT>ence <FONT STYLE="letter-spacing: 0.05pt">i</FONT>n
this p<FONT STYLE="letter-spacing: -0.3pt">r</FONT>ospectus supplement. This summary does not contain all of the informat<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on
that you should consider be<FONT STYLE="letter-spacing: 0.05pt">f</FONT>o<FONT STYLE="letter-spacing: -0.3pt">r</FONT>e deciding to invest
in our Common Stock. <FONT STYLE="letter-spacing: -0.75pt">Y</FONT>ou should <FONT STYLE="letter-spacing: -0.3pt">r</FONT>ead this ent<FONT STYLE="letter-spacing: 0.05pt">i</FONT><FONT STYLE="letter-spacing: -0.3pt">r</FONT>e
p<FONT STYLE="letter-spacing: -0.3pt">r</FONT>ospectus supplement and the ac<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ompanying p<FONT STYLE="letter-spacing: -0.3pt">r</FONT>ospectus
ca<FONT STYLE="letter-spacing: -0.25pt">r</FONT>efull<FONT STYLE="letter-spacing: -0.45pt">y</FONT>, <FONT STYLE="letter-spacing: 0.05pt">i</FONT>ncluding
the consolida<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ed financial sta<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ements and other
information incorporated by <FONT STYLE="letter-spacing: -0.25pt">r</FONT>efe<FONT STYLE="letter-spacing: -0.35pt">r</FONT>ence into this
p<FONT STYLE="letter-spacing: -0.3pt">r</FONT>ospectus supplement and the accompanying p<FONT STYLE="letter-spacing: -0.25pt">r</FONT>ospectus
befo<FONT STYLE="letter-spacing: -0.3pt">r</FONT>e making an investment de<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ision. If you invest
in our Common Stock, you a<FONT STYLE="letter-spacing: -0.3pt">r</FONT>e assuming a high deg<FONT STYLE="letter-spacing: -0.3pt">r</FONT>ee
of risk. See the &ldquo;Risk Fac<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ors&rdquo; se<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tion
of <FONT STYLE="letter-spacing: 0.05pt">t</FONT>his p<FONT STYLE="letter-spacing: -0.25pt">r</FONT>ospectus supplement beginning on page
<FONT STYLE="letter-spacing: 0.95pt">S-7</FONT>, the risk factors con<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ained in our Annual
R<FONT STYLE="letter-spacing: 0.05pt">e</FONT>port on <FONT STYLE="letter-spacing: 0.05pt">F</FONT>orm 10-K <FONT STYLE="letter-spacing: 0.05pt">f</FONT>or
the year ended June 30, 2025, ea<FONT STYLE="letter-spacing: 0.05pt">c</FONT>h of our Quarterly Reports on Form 10-Q, and in our other
subsequent filings w<FONT STYLE="letter-spacing: 0.05pt">i</FONT>th the SEC.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>About Lunai Bioworks Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">The <FONT STYLE="letter-spacing: 0.05pt">C</FONT>ompany
was <FONT STYLE="letter-spacing: 0.05pt">i</FONT>ncorporated on January 18, 2011 under the laws of the St<FONT STYLE="letter-spacing: 0.05pt">a</FONT>te
of De<FONT STYLE="letter-spacing: 0.05pt">l</FONT>aware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Lunai Bioworks Inc. operates
through two subsidiaries, Renovaro Biosciences, Inc. (&ldquo;Renovaro Biosciences&rdquo;) and Biosymetrics, Inc. (&ldquo;Biosymetrics&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Renovaro Biosciences </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Biosciences is a biotechnology
company intending, subject to completion of necessary capital raising, to develop advanced allogeneic cell and gene therapies to promote
stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially
to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Allogeneic Cell Therapy</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The strategic benefit of the
allogeneic cell therapy technologies is to potentially allow for the manufacture of large, &ldquo;off-the-shelf&rdquo; banks of therapeutic
cells that are readily available on demand by healthcare professionals, to potentially decrease the time between diagnosis and treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In certain treatments (e.g.,
HIV and cancer), cells taken from healthy donors are engineered to introduce signaling molecules that are designed to enhance the ability
of specific immune cells to recognize diseased cells, and to help recruit other cells that will destroy cancer or virus infected cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Gene Therapy</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Renovaro Biosciences may also
seek to explore various approaches for gene therapy design elements to potentially eliminate virus-infected or cancer cells by the modulation
of patient&rsquo;s immune system. Upon injecting into the patients, these genetically engineered allogeneic cells have little to no risk
of passing those modifications to the patient since they are terminally differentiated with locked functionality to activate the host
immune system. Gene modified allogeneic cells are expected to be rejected naturally once they activate the patient&rsquo;s immune system
therefore will have a very short survival time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>BioSymetrics Overview</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="text-indent: 36pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">BioSymetrics is a biomedical artificial intelligence
company focused on integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence,
to advance biomarker discovery, therapeutic development, and precision medicine. BioSymetrics has developed proprietary machine learning
pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. These insights are designed
to support pharmaceutical research, early disease detection, and personalized treatment strategies.</P>

<P STYLE="text-indent: 36pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 36pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">BioSymetrics collaborates with pharmaceutical companies,
healthcare providers, and academic institutions to co-develop analytical tools and translational research programs. Application areas
of the BioSymetrics platform include: (i) multi-omics integration for target identification and validation; (ii) predictive modeling of
therapeutic efficacy and safety; (iii) clinical trial optimization, including patient stratification and response monitoring; and (iv)
experimental screening of gene and small molecule effects for the purpose of identifying novel drug targets and therapeutics.</P>

<P STYLE="text-indent: 36pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 36pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The key to the BioSymetrics approach is Contingent
AI. In Contingent AI, any &ldquo;settable&rdquo; parameter for data processing, data integration, or feature selection is permuted and
the corresponding effects on the downstream predictive model measured. This process is similar in nature to hyperparameter tuning in machine
learning, however instead of optimizing only the machine learning model, the entire data science pipeline (including model selection)
is subject to optimization. We have applied this method extensively in drug discovery, producing marked improvements in experiment interpretation
and lead generation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Name Change</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 18, 2025, the Company
filed a Certificate of Amendment to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to
change its corporate name from &ldquo;Renovaro Inc.&rdquo; to &ldquo;Lunai Bioworks Inc.&rdquo; (the &ldquo;Name Change&rdquo;). The Name
Change became effective on August 20, 2025. The Company changed its name to signify its focus on the development and validation of its
AI-driven cancer diagnostics platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Exchange of Secured Promissory Notes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 7, 2025, the Company entered
into an Exchange Agreement (the &ldquo;Exchange Agreement&rdquo;) with certain accredited investors (the &ldquo;Investors&rdquo;), all
of whom were existing shareholders of the Company. Pursuant to the Exchange Agreement, the Investors agreed to exchange an aggregate of
$9.7 million in outstanding secured promissory notes (the &ldquo;Secured Notes&rdquo;) for $16.1 million in new convertible promissory
notes (the &ldquo;Convertible Notes&rdquo;), representing a 65% premium to the principal and interest amount of the Secured Notes. The
Convertible Notes had a maturity date of July 31, 2025 and did not bear any interest. The exchange was completed to restructure the Company&rsquo;s
debt obligations and provide additional flexibility to support strategic initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Immediately following the issuance
of the Convertible Notes on July 7, 2025, the Investors elected to convert the entire $16.1 million principle amount into an aggregate
of 53.6 million shares of common stock (the &ldquo;Conversion Shares&rdquo;), based on the stated $0.30 per share conversion price. The
$0.30 per share conversion price of the Convertible Notes represented a premium to the closing price of the Company&rsquo;s common stock
on July 7, 2025, the date of execution and conversion. As a result of the foregoing transactions, the Company (i) eliminated $9.7 million
of secured indebtedness, (ii) issued $16.1 million in Convertible Notes to the same holders, and (iii) issued 53.6 million shares of common
stock upon full conversion of such Convertible Notes. The transactions did not involve any cash proceeds to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Acquisition of Biosymetrics, Inc. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 8, 2025, Lunai completed
the acquisition of Biosymetrics, Inc., a Delaware corporation (&ldquo;Biosymetrics&rdquo;), an artificial intelligence (AI)-driven drug
discovery and biomarker identification company, by merger of Renovaro Acquisition Sub, a Delaware corporation and wholly owned subsidiary
of the Company with Biosymetrics, with Biosymetrics as the surviving corporation and a wholly owned subsidiary of Lunai. The Company issued
15.0 million shares of our Common Stock to the former stockholders of Biosymetrics in accordance with the terms of the merger agreement.
Pursuant to the acquisition, the Company gained access to BioSymetrics&rsquo; proprietary Elion platform, a cutting-edge AI and machine
learning engine that uncovers complex biological relationships to accelerate the discovery of diagnostics and therapeutics. BioSymetrics&rsquo;
Phenograph provides a translational engine that maps human clinical signals to prioritized therapeutic targets and is designed to expedite
and improve target and biomarker identification and enable patient stratification and drug repurposing. BioSymetrics&rsquo; advanced AI
in vivo modeling and machine vision systems enable high throughput phenotypic screening, leveraging AI-powered analysis to detect subtle
biological responses with unprecedented accuracy. By integrating Elion into Lunai&rsquo;s workflow, the combined entity aims to streamline
the translation of biomarker insights into accelerated discovery timelines, enhancing precision in target identification and improving
overall research efficiency, ultimately enabling faster and more effective drug discovery and therapeutic development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Reverse Stock Sp<FONT STYLE="letter-spacing: 0.05pt">l</FONT>it</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.7pt">W</FONT>e
filed with <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he Del<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ware S<FONT STYLE="letter-spacing: 0.05pt">e</FONT>cretary
of State a Certific<FONT STYLE="letter-spacing: 0.05pt">a</FONT>te of Amendment to our Cert<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ficate
of Incorporat<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on (the &ldquo;Certif<FONT STYLE="letter-spacing: 0.05pt">i</FONT>cate of Amendment&rdquo;)
whi<FONT STYLE="letter-spacing: 0.05pt">c</FONT>h became e<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fective at 12:01 a.m. on September
<FONT STYLE="letter-spacing: 0.15pt">29</FONT>, 2025 (the &ldquo;E<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fective <FONT STYLE="letter-spacing: -0.3pt">T</FONT>ime&rdquo;)
to e<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fect a one-fo<FONT STYLE="letter-spacing: -0.15pt">r</FONT>-ten (1:10) reverse stock
<FONT STYLE="letter-spacing: 0.05pt">s</FONT>plit (the &ldquo;<FONT STYLE="letter-spacing: 0.05pt">R</FONT>everse Stock Sp<FONT STYLE="letter-spacing: 0.05pt">l</FONT>it&rdquo;)
of the sh<FONT STYLE="letter-spacing: 0.05pt">a</FONT>res of our Common Stock. The Reverse Stock Split was approved by our stockhold<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rs
at a special me<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ting of the stockholders o<FONT STYLE="letter-spacing: 1.75pt">n</FONT>August
15, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result of the Reverse Stock
Split, every ten (10) shares of issued <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd outstanding <FONT STYLE="letter-spacing: 0.05pt">C</FONT>ommon
Stock were auto<FONT STYLE="letter-spacing: 0.05pt">m</FONT>atically combined <FONT STYLE="letter-spacing: 0.05pt">i</FONT>nto one (1)
issued and outstanding share of Co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>mon Stock, wi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>hout
any ch<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nge in the par value per share. No fractional shares were issued as a result of the
Reverse Sto<FONT STYLE="letter-spacing: 0.05pt">c</FONT>k Split, and <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ny fra<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tional
share resulting frm the Reverse Stock Split was rounded up to the next whole number. The shares of Common Stock underlying the outstanding
stock options and warran<FONT STYLE="letter-spacing: 0.05pt">t</FONT>s were similarly adjusted <FONT STYLE="letter-spacing: 0.05pt">a</FONT>long
with corresponding ad<FONT STYLE="letter-spacing: 0.05pt">j</FONT>ustments <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o their exercise
prices. The Reverse Stock Split also proport<FONT STYLE="letter-spacing: 0.05pt">i</FONT>onally reduced the <FONT STYLE="letter-spacing: 0.05pt">t</FONT>otal
number of outstanding shares of Common Stock from 231,780,434 shares to 23,178,096 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Nasdaq Listing Status</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Nasdaq Minimum Bid Price Requi<FONT STYLE="letter-spacing: -0.3pt">r</FONT>ement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 12, 2024, the Company
received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;) notifying the Company
that for the prior 30 consecutive business days the bid price for the Company&rsquo;s common stock had closed below the minimum $1.00
per share requirement for continued inclusion on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (Bid Price Rule). The deficiency letter
did not result in the immediate delisting of the Company&rsquo;s common stock from Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A),
the Company was provided an initial period of 180 calendar days, until March 11, 2025, to regain compliance with the Bid Price Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 14, 2025, the Company
received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;) notifying the Company
that for the prior 30 consecutive business days the bid price for the Company&rsquo;s common stock had closed below the minimum $1.00
per share requirement for continued inclusion on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (Bid Price Rule). The deficiency letter
did not result in the immediate delisting of the Company&rsquo;s common stock from Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A),
the Company was provided an initial period of 180 calendar days, until October 13, 2025, to regain compliance with the Bid Price Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">On
October 15, 2025, Lunai Bioworks (the &ldquo;Company&rdquo;) received a Notice from the NASDAQ Stock Market that the Company has regained
compliance with Listing Rule&nbsp;5550(a)(2). On April&nbsp;14, 2025, the NASDAQ staff notified the Company that its common stock failed
to maintain a minimum bid price of $1.00 over the previous thirty (30) consecutive business days as required by the Listing Rules of the
NASDAQ Stock Market. Since then, the staff of NASDAQ has determined that for the last eleven (11) consecutive business days from September&nbsp;30,
2025 to October&nbsp;14, 2025, the closing bid price of the Company&rsquo;s common stock has been at $1.00 per share or greater.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Failure to Hold Annual Meeting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 7, 2025, the Company received
a written notice from Nasdaq notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5620(a), which requires
that listed companies hold an annual meeting of shareholders no later than one year after the end of their fiscal year. Pursuant to Nasdaq
Listing Rule 5810(c)(2)(G), the Company had 45 calendar days from the date of the Notice to submit a plan to regain compliance. The Company
submitted a compliance plan and on August 5, 2025, the Company received written confirmation from Nasdaq that it had accepted the Company&rsquo;s
plan to regain compliance and granted an extension until October 31, 2025, for the Company to hold its annual meeting of shareholders.
The Company held its annual meeting of its shareholders prior to October 31, 2025. On November 4, 2025, Nasdaq notified the Company that
it had determined that the Company was in compliance with Rule 5620(a) and the matter is closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Implications of Being a Small<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r
Reporting Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.7pt">W</FONT>e are
a &ldquo;smaller reporting comp<FONT STYLE="letter-spacing: 0.05pt">a</FONT>n<FONT STYLE="letter-spacing: -0.55pt">y</FONT>,&rdquo; me<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ning
that the mark<FONT STYLE="letter-spacing: 0.05pt">e</FONT>t value of our stock held by non-a<FONT STYLE="letter-spacing: -0.1pt">f</FONT>filiates
is less than $700 mill<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on as of our most recently comple<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ed
s<FONT STYLE="letter-spacing: 0.05pt">e</FONT>cond f<FONT STYLE="letter-spacing: 0.05pt">i</FONT>scal quarter and our annual revenue was
less than $100 million during our most recently compl<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ted fiscal yea<FONT STYLE="letter-spacing: -0.45pt">r</FONT>.
<FONT STYLE="letter-spacing: -0.7pt">W</FONT>e <FONT STYLE="letter-spacing: 0.05pt">m</FONT>ay <FONT STYLE="letter-spacing: 0.05pt">c</FONT>ontinue
to be a s<FONT STYLE="letter-spacing: 0.05pt">m</FONT>aller reporting company if ei<FONT STYLE="letter-spacing: 0.05pt">t</FONT>her (<FONT STYLE="letter-spacing: 0.05pt">i</FONT>)
<FONT STYLE="letter-spacing: 0.05pt">t</FONT>he market value of our stock held by non-a<FONT STYLE="letter-spacing: -0.15pt">f</FONT>filiates
is less than $250 mil<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ion or (i<FONT STYLE="letter-spacing: 0.05pt">i</FONT>) our annual rev<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nue
w<FONT STYLE="letter-spacing: 0.05pt">a</FONT>s <FONT STYLE="letter-spacing: 0.05pt">l</FONT>ess than $100 million during <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he
most recen<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ly co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>pleted fiscal year <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd
the market value of our stock held by non-a<FONT STYLE="letter-spacing: -0.1pt">f</FONT>filiates is less than $700 million as of our most
r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>cently completed second fiscal quar<FONT STYLE="letter-spacing: 0.05pt">t</FONT>e<FONT STYLE="letter-spacing: -0.45pt">r</FONT>.
As a smal<FONT STYLE="letter-spacing: 0.05pt">l</FONT>er repor<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ing co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>pan<FONT STYLE="letter-spacing: -0.55pt">y</FONT>,
we <FONT STYLE="letter-spacing: 0.05pt">a</FONT>re per<FONT STYLE="letter-spacing: 0.05pt">m</FONT>itted and intend to r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ly
on exempt<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ons from cert<FONT STYLE="letter-spacing: 0.05pt">a</FONT>in dis<FONT STYLE="letter-spacing: 0.05pt">c</FONT>losure
requirements that are applicab<FONT STYLE="letter-spacing: 0.05pt">l</FONT>e to other public co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>panies
that are not smaller report<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our principal o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fices
are <FONT STYLE="letter-spacing: 0.05pt">l</FONT>ocated at 3400 Cottage Way, Suite G2 #32562, Sacramento, CA 95825, and our tel<FONT STYLE="letter-spacing: 0.05pt">e</FONT>phone
number is (424) 222-9301. Our website address is www.lunaibioworks.com; <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he reference <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o
such website <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ddress does not consti<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ute incorporation
by reference of the information cont<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ined on the websi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>e
and such information should not be <FONT STYLE="letter-spacing: 0.05pt">c</FONT>onsidered part of this prospec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>




<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><A NAME="a_004"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 253.5pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.7pt"><I>The</I></FONT><I>
<FONT STYLE="letter-spacing: 0.05pt">f</FONT>ollowing summary contains basic information about this offering. The summary is not intended
to be complete. <FONT STYLE="letter-spacing: -0.75pt">Y</FONT>ou should <FONT STYLE="letter-spacing: -0.3pt">r</FONT>ead the fu<FONT STYLE="letter-spacing: 0.05pt">l</FONT>l
<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ext and mo<FONT STYLE="letter-spacing: -0.25pt">r</FONT>e specific d<FONT STYLE="letter-spacing: 0.05pt">e</FONT>tails
contained elsewhe<FONT STYLE="letter-spacing: -0.25pt">r</FONT>e in this p<FONT STYLE="letter-spacing: -0.25pt">r</FONT>ospectus supplement
and the accompanying p<FONT STYLE="letter-spacing: -0.25pt">r</FONT>ospectus. Unless otherwise ind<FONT STYLE="letter-spacing: 0.05pt">i</FONT>cated,
all in<FONT STYLE="letter-spacing: 0.05pt">f</FONT>ormation contained <FONT STYLE="letter-spacing: 0.05pt">i</FONT>n this p<FONT STYLE="letter-spacing: -0.3pt">r</FONT>ospectus
supplement <FONT STYLE="letter-spacing: -0.3pt">r</FONT>eflects the R<FONT STYLE="letter-spacing: 0.05pt">e</FONT>verse Stock Spli<FONT STYLE="letter-spacing: 0.05pt">t</FONT>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><I>&nbsp;&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; width: 24%; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: normal; line-height: normal; word-spacing: normal"><B>Common
    Stock offered by us:</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 0pt; width: 75%; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: normal; line-height: normal; word-spacing: normal">Shares
    of Common Stock having an aggregate offering amount of up to $11,702,826.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: normal; line-height: normal; word-spacing: normal"><B>Common
    Stock to be outstanding after the offering</B></FONT></TD>
    <TD><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">32,364,108 shares, assuming the issuance of 8,933,455 shares in this offering
at an assumed offering price of $1.31 per share, which was the last reported sale price of our Common Stock on Nasdaq on December 1, 2025.
The actual number of shares issued will vary depending on how many shares of our Common Stock we choose to sell and the prices at which
such sales occur.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: normal; line-height: normal; word-spacing: normal"><B>Plan
    of Distribution</B></FONT></TD>
    <TD><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: normal; line-height: normal; word-spacing: normal">Sales
    of our Common Stock, if any, under this prospectus supplement and the accompanying prospectus may be made by any method permitted
    by law deemed to be an &ldquo;at-the-market&rdquo; offering as defined in Rule 415 of the Securities Act, including without limitation
    sales made directly on Nasdaq, on any other existing trading market for the common stock in the United States. Dawson James is not
    required to sell any certain number of shares or dollar amount of our Common Stock, but will act as a sales agent and use commercially
    reasonable efforts to sell on our behalf all of the shares of Common Stock requested to be sold by us, consistent with its normal
    trading and sales practices, subject to the terms of the sales agreement. See section titled &ldquo;<I>Plan of Distribution</I>&rdquo;
    on page S-14 of this prospectus supplement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: normal; line-height: normal; word-spacing: normal"><B>Use
    of Proceeds</B></FONT></TD>
    <TD><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: normal; line-height: normal; word-spacing: normal">We
    currently intend to use the net proceeds from these sales for general corporate purposes, including working capital, operating expenses,
    and capital expenditures. See &ldquo;<I>Use of Proceeds</I>&rdquo; on page S-10 of this prospectus supplement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: normal; line-height: normal; word-spacing: normal"><B>Risk
    Factors</B></FONT></TD>
    <TD><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: normal; line-height: normal; word-spacing: normal"><B><I>An
    investment in our securities is highly speculative and subject to substantial risks</I>.</B> You should consider the &ldquo;<I>Risk
    Factors</I>&rdquo; and the &ldquo;<I>Cautionary Note Regarding Forward-Looking Statements</I>&rdquo; included and incorporated by
    reference in this prospectus supplement and the accompanying prospectus, including the risk factors incorporated by reference from
    our filings with the SEC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: normal; line-height: normal; word-spacing: normal"><B>Nasdaq
    Capital Market symbol</B></FONT></TD>
    <TD><FONT STYLE="letter-spacing: normal; line-height: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: normal; line-height: normal; word-spacing: normal">Our
    Common Stock is listed on the Nasdaq Capital Market under the symbol &ldquo;LNAI.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">The number of shares of our Common S<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ock
to be outstanding <FONT STYLE="letter-spacing: 0.05pt">i</FONT>mmediate<FONT STYLE="letter-spacing: 0.05pt">l</FONT>y after this o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering
is based on <FONT STYLE="letter-spacing: 0.35pt">23,430,653</FONT> shares of <FONT STYLE="letter-spacing: 0.05pt">C</FONT>ommon Stock
<FONT STYLE="letter-spacing: 0.05pt">a</FONT>s of December 1, 2025, which exc<FONT STYLE="letter-spacing: 0.05pt">l</FONT>udes:<FONT STYLE="line-height: 107%"><SUP></SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in">&nbsp;</TD>
<TD STYLE="width: 0.25in; text-align: left">&#9679;</TD>
<TD STYLE="text-align: justify">267,695 shares of Common Stock issuable in connection with the acquisition of Renovaro Cube as contingent consideration;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD>
<TD STYLE="text-align: justify">626,983 shares of Common Stock issuable upon the exercise of warrants at a weighted average exercise prices of $9.09 per share;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD>
<TD STYLE="text-align: justify">242,482 shares of Common Stock issuable upon the exercise of options at a weighted average exercise price of $7.37 per share.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.6pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">Unless otherwise indicat<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d,
a<FONT STYLE="letter-spacing: 0.05pt">l</FONT>l information in this prospectus reflec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>s the
<FONT STYLE="letter-spacing: 0.05pt">R</FONT>everse Stock Split and assumes no issuance of the outstanding contingent consideration described
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>




<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>RISK <FONT STYLE="letter-spacing: -0.65pt">F</FONT>AC<FONT STYLE="letter-spacing: -0.15pt"><A NAME="a_005"></A>T</FONT>ORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 254.7pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><I>Investing in our securities
is highly spe<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ulative and involves a high deg<FONT STYLE="letter-spacing: -0.3pt">r</FONT>ee
of r<FONT STYLE="letter-spacing: 0.05pt">i</FONT>sk. Befo<FONT STYLE="letter-spacing: -0.3pt">r</FONT>e dec<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ding
<FONT STYLE="letter-spacing: 0.05pt">w</FONT>hether to invest in our securit<FONT STYLE="letter-spacing: 0.05pt">i</FONT>es, <FONT STYLE="letter-spacing: 0.05pt">y</FONT>ou
should ca<FONT STYLE="letter-spacing: -0.3pt">r</FONT>efully <FONT STYLE="letter-spacing: 0.05pt">c</FONT>onsider the risk factors we
describe in this p<FONT STYLE="letter-spacing: -0.25pt">r</FONT>ospectus supplement, in the accompanying p<FONT STYLE="letter-spacing: -0.3pt">r</FONT>ospectus,
in any <FONT STYLE="letter-spacing: -0.25pt">r</FONT>elated f<FONT STYLE="letter-spacing: -0.3pt">r</FONT>ee writing p<FONT STYLE="letter-spacing: -0.3pt">r</FONT>ospectus
that <FONT STYLE="letter-spacing: 0.05pt">w</FONT>e may authorize to be p<FONT STYLE="letter-spacing: -0.25pt">r</FONT>ovided to you or
<FONT STYLE="letter-spacing: 0.05pt">i</FONT>n any <FONT STYLE="letter-spacing: -0.3pt">r</FONT>eport in<FONT STYLE="letter-spacing: 0.05pt">c</FONT>orporated
by <FONT STYLE="letter-spacing: -0.3pt">r</FONT>efe<FONT STYLE="letter-spacing: -0.3pt">r</FONT>ence <FONT STYLE="letter-spacing: 0.05pt">i</FONT>nto
this p<FONT STYLE="letter-spacing: -0.3pt">r</FONT>ospectus supplement, inc<FONT STYLE="letter-spacing: 0.05pt">l</FONT>uding our Annual
Report on Form 10-K, and all amendments thereto, for the year ended June 30, 2025, ea<FONT STYLE="letter-spacing: 0.05pt">c</FONT>h of
our Quarterly Reports on Form 10-Q, and in our other subsequent filings w<FONT STYLE="letter-spacing: 0.05pt">i</FONT>th the SEC. Although
we discuss <FONT STYLE="letter-spacing: 0.05pt">k</FONT>ey <FONT STYLE="letter-spacing: 0.05pt">r</FONT>isks <FONT STYLE="letter-spacing: 0.05pt">i</FONT>n
those risk factor descript<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ons, addit<FONT STYLE="letter-spacing: 0.05pt">i</FONT>onal ris<FONT STYLE="letter-spacing: 0.05pt">k</FONT>s
not cur<FONT STYLE="letter-spacing: -0.3pt">r</FONT>ently <FONT STYLE="letter-spacing: 0.05pt">k</FONT>nown to us or that we cur<FONT STYLE="letter-spacing: -0.3pt">r</FONT>ently
deem <FONT STYLE="letter-spacing: 0.05pt">i</FONT>mmaterial also <FONT STYLE="letter-spacing: 0.05pt">m</FONT>ay impair our busin<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ss.
Our subsequent f<FONT STYLE="letter-spacing: 0.05pt">i</FONT>lings with the SEC may contain amended and updated discussions of significant
risk<FONT STYLE="letter-spacing: 0.05pt">s</FONT>. <FONT STYLE="letter-spacing: -0.75pt">W</FONT>e cannot p<FONT STYLE="letter-spacing: -0.3pt">r</FONT>edict
fu<FONT STYLE="letter-spacing: 0.05pt">t</FONT>u<FONT STYLE="letter-spacing: -0.3pt">r</FONT>e risks or estimate the extent to <FONT STYLE="letter-spacing: 0.05pt">w</FONT>hich
they may a<FONT STYLE="letter-spacing: 0.05pt">f</FONT>fect our finan<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ial performance. The
occur<FONT STYLE="letter-spacing: -0.3pt">r</FONT>ence of any of these r<FONT STYLE="letter-spacing: 0.05pt">i</FONT>sks might cause <FONT STYLE="letter-spacing: 0.05pt">y</FONT>ou
to lose all or part of your investment in <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he Common Stock.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><I>&nbsp;</I></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>Risks Related to This Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 229.5pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="letter-spacing: -0.95pt"><B><I>Y</I></B></FONT><B><I>ou may
experien<FONT STYLE="letter-spacing: 0.05pt">c</FONT>e imm<FONT STYLE="letter-spacing: 0.05pt">e</FONT>diate and substantial dilution
as a result of this o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fering. <FONT STYLE="letter-spacing: -0.95pt">Y</FONT>ou <FONT STYLE="letter-spacing: 0.05pt">m</FONT>ay
also experience future dilution as a r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>sult of future <FONT STYLE="letter-spacing: 0.05pt">e</FONT>quity
o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>ferings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering price per share in
this o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fering <FONT STYLE="letter-spacing: 0.05pt">m</FONT>ay ex<FONT STYLE="letter-spacing: 0.05pt">c</FONT>eed
the n<FONT STYLE="letter-spacing: 0.05pt">e</FONT>t <FONT STYLE="letter-spacing: 0.05pt">t</FONT>angible book v<FONT STYLE="letter-spacing: 0.05pt">a</FONT>lue
p<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r share of our common stock outstanding prior <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o
th<FONT STYLE="letter-spacing: 0.05pt">i</FONT>s o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering. Our h<FONT STYLE="letter-spacing: 0.05pt">i</FONT>storical
net <FONT STYLE="letter-spacing: 0.05pt">t</FONT>angible book value as of <FONT STYLE="letter-spacing: 0.4pt">September 30, </FONT>2025
was $(19.2) mill<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on, or <FONT STYLE="letter-spacing: 0.05pt">a</FONT>pproximately $(0.83)
per share of our <FONT STYLE="letter-spacing: 0.05pt">C</FONT>ommon Stock. Assuming that an aggregate <FONT STYLE="letter-spacing: 0.05pt">a</FONT>mount
of $11,702,826 of our Common Stock is <FONT STYLE="letter-spacing: 0.05pt">s</FONT>old at <FONT STYLE="letter-spacing: 0.05pt">a</FONT>n
assumed o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fering price of $1.31 per shar<FONT STYLE="letter-spacing: 0.05pt">e</FONT>, the
<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ast reported sale pr<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ce of our Common Stock on
Nasdaq on December 1, 2025, our as adjusted net tangible book value as of September 30, 2025 would h<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ve
been ($7.49) million, or approxim<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tely ($0.23) per share of our Common Stock. <FONT STYLE="letter-spacing: 0.05pt">T</FONT>his
represents an immedia<FONT STYLE="letter-spacing: 0.05pt">t</FONT>e increase in net tangible book value of $0.59 per share of our Common
Stock to new investors in this o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering, represen<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ing
the di<FONT STYLE="letter-spacing: -0.1pt">f</FONT>ference betwe<FONT STYLE="letter-spacing: 0.05pt">e</FONT>n the assumed o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering
price in <FONT STYLE="letter-spacing: 0.05pt">t</FONT>his o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fering and our as adjusted net
t<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ngible book value as of September 30, 2025. Further<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ore,
<FONT STYLE="letter-spacing: 0.05pt">i</FONT>f outs<FONT STYLE="letter-spacing: 0.05pt">t</FONT>anding op<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ions
or warran<FONT STYLE="letter-spacing: 0.05pt">t</FONT>s are ex<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rcised, outstanding restric<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ed
s<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ock un<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ts v<FONT STYLE="letter-spacing: 0.05pt">e</FONT>st
or secur<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ties that are convertible or exercisable <FONT STYLE="letter-spacing: 0.05pt">i</FONT>nto
Common Stock are <FONT STYLE="letter-spacing: 0.05pt">c</FONT>onverted or exercised, you could <FONT STYLE="letter-spacing: 0.05pt">e</FONT>xperience
further di<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">In <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ddition,
we have a signifi<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ant number of stock options and warrants ou<FONT STYLE="letter-spacing: 0.05pt">t</FONT>standing,
and, in order to raise addi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ional capit<FONT STYLE="letter-spacing: 0.05pt">a</FONT>l, we
may in the future o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fer <FONT STYLE="letter-spacing: 0.05pt">a</FONT>dditional sh<FONT STYLE="letter-spacing: 0.05pt">a</FONT>res
of our Common <FONT STYLE="letter-spacing: 0.05pt">S</FONT>tock or other s<FONT STYLE="letter-spacing: 0.05pt">e</FONT>curities <FONT STYLE="letter-spacing: 0.05pt">c</FONT>onvertible
into or exchangeable for our Common S<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ock at pric<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s
that m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>y not be the same as the pri<FONT STYLE="letter-spacing: 0.05pt">c</FONT>e p<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r
share in this o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fering. In the event that the outstanding options or warrants are exercis<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d
or settl<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d, or that we <FONT STYLE="letter-spacing: 0.05pt">m</FONT>ake <FONT STYLE="letter-spacing: 0.05pt">a</FONT>dditional
issuances of Common Stock or o<FONT STYLE="letter-spacing: 0.05pt">t</FONT>her convertible or exchangeable securities, you could experien<FONT STYLE="letter-spacing: 0.05pt">c</FONT>e
additional dilution. <FONT STYLE="letter-spacing: -0.65pt">W</FONT>e cannot <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ssure you that
we will be <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ble to sell shares or oth<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r se<FONT STYLE="letter-spacing: 0.05pt">c</FONT>urities
in any other o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fering at a price p<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r share th<FONT STYLE="letter-spacing: 0.05pt">a</FONT>t
<FONT STYLE="letter-spacing: 0.05pt">i</FONT>s <FONT STYLE="letter-spacing: 0.05pt">e</FONT>qual to or grea<FONT STYLE="letter-spacing: 0.05pt">t</FONT>er
<FONT STYLE="letter-spacing: 0.05pt">t</FONT>han <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he pr<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ce
per sh<FONT STYLE="letter-spacing: 0.05pt">a</FONT>re p<FONT STYLE="letter-spacing: 0.05pt">a</FONT>id by inves<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ors
in this o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering, and investors purch<FONT STYLE="letter-spacing: 0.05pt">a</FONT>sing shares
or other se<FONT STYLE="letter-spacing: 0.05pt">c</FONT>urities in the future could have righ<FONT STYLE="letter-spacing: 0.05pt">t</FONT>s
superior to existing stockholders, <FONT STYLE="letter-spacing: 0.05pt">i</FONT>ncluding <FONT STYLE="letter-spacing: 0.05pt">i</FONT>nvestors
who purchase shares of Common S<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ock in this o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering.
The price per share at which we sell additional shares of our Common Stock or se<FONT STYLE="letter-spacing: 0.05pt">c</FONT>urities convertible
or exercisable into Common Stock in future transactions, m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>y be higher or lower th<FONT STYLE="letter-spacing: 0.05pt">a</FONT>n
the price per share you pay in this o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering. As a r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>sult,
purchasers of the shares we sell <FONT STYLE="letter-spacing: 0.05pt">i</FONT>n this o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering,
as w<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ll <FONT STYLE="letter-spacing: 0.05pt">a</FONT>s our existing stockholders, will experience
significant dilu<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ion if we sell <FONT STYLE="letter-spacing: 0.05pt">a</FONT>t pri<FONT STYLE="letter-spacing: 0.05pt">c</FONT>es
signif<FONT STYLE="letter-spacing: 0.05pt">i</FONT>cantly below <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he price at which they <FONT STYLE="letter-spacing: 0.05pt">i</FONT>nvested.
See the sect<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on entitled &ldquo;<I>D<FONT STYLE="letter-spacing: 0.05pt">i</FONT>lution</I>&rdquo;
below for a more detailed i<FONT STYLE="letter-spacing: 0.05pt">l</FONT>lustration of the di<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ution
you would incur if you parti<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ipated in this o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>The market price of our Common Stock has been vola<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ile
and may cont<FONT STYLE="letter-spacing: 0.05pt">i</FONT>nue to be volati<FONT STYLE="letter-spacing: 0.05pt">l</FONT>e due <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o
numerous <FONT STYLE="letter-spacing: 0.05pt">c</FONT>ircumstances beyond our control, and stockholders could lose a<FONT STYLE="letter-spacing: 0.05pt">l</FONT>l
or part of their inv<FONT STYLE="letter-spacing: 0.05pt">e</FONT>stment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">The market price of our Common Stock has b<FONT STYLE="letter-spacing: 0.05pt">e</FONT>en
and <FONT STYLE="letter-spacing: 0.05pt">m</FONT>ay continue to be h<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ghly volati<FONT STYLE="letter-spacing: 0.05pt">l</FONT>e.
Our sto<FONT STYLE="letter-spacing: 0.05pt">c</FONT>k price <FONT STYLE="letter-spacing: 0.05pt">c</FONT>ould be subj<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ct
to wide fluctu<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tions in response to a variety of fa<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tors,
including, without <FONT STYLE="letter-spacing: 0.05pt">l</FONT>imitat<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
<TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">future announc<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ments about us, our collaborators,
or competitors, including the results of <FONT STYLE="letter-spacing: 0.05pt">t</FONT>esting, technological innovat<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ons,
or new produ<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ts and services;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the level of expenses related to any of our product candidates or clinical development programs;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">additions or departures of key p<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rsonnel;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">operating results th<FONT STYLE="letter-spacing: 0.05pt">a</FONT>t fall below exp<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ctations;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">announcements by us rela<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ing to any strateg<FONT STYLE="letter-spacing: 0.05pt">i</FONT>c
relationship;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">sales, or the percep<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ion that future sal<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s
may occu<FONT STYLE="letter-spacing: -0.3pt">r</FONT>, of equity securities or issuance of deb<FONT STYLE="letter-spacing: 0.05pt">t</FONT>;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">generic economic, industry and market conditions;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">changes in stat<FONT STYLE="letter-spacing: 0.05pt">e</FONT>, provincial, or federal r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>gulations
a<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fecting us and our industry;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">market conditions in the pharmaceutical and biotechnology sectors;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the continued la<FONT STYLE="letter-spacing: -0.1pt">r</FONT>ge fluctuations in major s<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ock
market indexes wh<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ch causes investors <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o sell
our Common Stock;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">economic, polit<FONT STYLE="letter-spacing: 0.05pt">i</FONT>cal, and other ext<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rnal
factors; and</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">period-to-period fluctua<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ions in our financial
r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>sults.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 16.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In add<FONT STYLE="letter-spacing: 0.05pt">i</FONT>tion,
the stock market in genera<FONT STYLE="letter-spacing: 0.05pt">l</FONT>, and the markets for biotechnology, pharmaceutical and technology
stocks in particular, have experienced extr<FONT STYLE="letter-spacing: 0.05pt">e</FONT>me price and volume fluctuations that have oft<FONT STYLE="letter-spacing: 0.05pt">e</FONT>n
been unrelated or disproport<FONT STYLE="letter-spacing: 0.05pt">i</FONT>onate <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o the operating
performance of the issue<FONT STYLE="letter-spacing: -0.45pt">r</FONT>. During <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he 12-month
period <FONT STYLE="letter-spacing: 0.05pt">e</FONT>nded December 1, 2025, our Common Stock has traded as h<FONT STYLE="letter-spacing: 0.05pt">i</FONT>gh
as $19.05 per share and as low as $0.83 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">These broad market fluctuations
<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ay adversely a<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fect the trading price of our
Common Stock. These and other external factors have <FONT STYLE="letter-spacing: 0.05pt">c</FONT>aused and may continue to c<FONT STYLE="letter-spacing: 0.05pt">a</FONT>use
<FONT STYLE="letter-spacing: 0.05pt">t</FONT>he m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>rket pri<FONT STYLE="letter-spacing: 0.05pt">c</FONT>e
<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd demand for our Co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>mon Stock to fluctuat<FONT STYLE="letter-spacing: 0.05pt">e</FONT>,
which may limit or prevent investors from r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>adily selling their shares of Common Stock and
may oth<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rwise negat<FONT STYLE="letter-spacing: 0.05pt">i</FONT>vely a<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fect
the liquid<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ty of our Co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>mon Stock. While the m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>rket
price of our Common Stock may r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>spond to developments regarding operating performance and
prosp<FONT STYLE="letter-spacing: 0.05pt">e</FONT>cts, <FONT STYLE="letter-spacing: 0.05pt">e</FONT>xpansion pl<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ns,
and developments regarding our <FONT STYLE="letter-spacing: 0.05pt">i</FONT>ndustr<FONT STYLE="letter-spacing: -0.55pt">y</FONT>, we bel<FONT STYLE="letter-spacing: 0.05pt">i</FONT>eve
<FONT STYLE="letter-spacing: 0.05pt">t</FONT>hat the extr<FONT STYLE="letter-spacing: 0.05pt">e</FONT>me vol<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tility
we exp<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rienced in r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>cent periods reflects market
and trading dynamics unrelat<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d to our underlying business, our ac<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ual
or expe<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ted op<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rating performance, our financial
condition, or macro or <FONT STYLE="letter-spacing: 0.05pt">i</FONT>ndustry fundamenta<FONT STYLE="letter-spacing: 0.05pt">l</FONT>s,
and we do not know if these dynamics w<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ll cont<FONT STYLE="letter-spacing: 0.05pt">i</FONT>nue
or how <FONT STYLE="letter-spacing: 0.05pt">l</FONT>ong they wi<FONT STYLE="letter-spacing: 0.05pt">l</FONT>l last. Under these circumstanc<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s,
we caution you against investing in our Com<FONT STYLE="letter-spacing: 0.05pt">m</FONT>on S<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ock,
unless you are prepared <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o incur the risk of losing a<FONT STYLE="letter-spacing: 0.05pt">l</FONT>l
or a substanti<FONT STYLE="letter-spacing: 0.05pt">a</FONT>l portion of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Future sales and issuances of our Common Stock
or rights to purchase Common Stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage
ownership of our stockholders and could cause our stock price to fall.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect that significant additional
capital will be needed in the future to continue our planned operations. To raise capital, we may sell substantial amounts of Common Stock
or securities convertible into or exchangeable for Common Stock in one or more transactions at prices and in a manner, we determine from
time to time. These future issuances of Common Stock or Common Stock-related securities, together with the exercise of outstanding options
or warrants, and any additional shares that may be issued in connection with acquisitions or licenses, if any, may result in material
dilution to our investors. Such sales may also result in material dilution to our existing stockholders, and new investors could gain
rights, preferences, and privileges senior to those of holders of our Common Stock. Pursuant to our equity incentive plans, our Compensation
Committee is authorized to grant equity-based incentive awards to our employees, non-employee directors and consultants. Future grants
of RSUs, options and other equity awards and issuances of Common Stock under our equity incentive plans will result in dilution and may
have an adverse effect on the market price of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have never paid dividends on our capital
stock and we do not anticipate paying dividends in the foreseeable future. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have never paid dividends on
any of our capital stock and currently intend to retain any future earnings to fund the growth of our business. Any determination to pay
dividends in the future will be at the discretion of our board of directors and will depend on our financial condition, operating results,
capital requirements, the requirements and contractual restrictions of then-existing debt instruments, general business conditions and
other factors that our board of directors may deem relevant. As a result, capital appreciation, if any, of our Common Stock will be the
sole source of gain for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are not current on foreign income and franchise
tax returns, reports and declarations in certain jurisdictions, which could cause the Company to incur fines or penalties. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The company is not current in
certain&nbsp;foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject due
to winding down of certain operations, (ii) has not paid all taxes and other governmental assessments and charges that are material in
amount, shown or determined to be due on such returns, reports and declarations. and (iii) has set aside on its books provision reasonably
adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If <FONT STYLE="letter-spacing: 0.05pt">w</FONT>e
are unable to continue to satisfy the app<FONT STYLE="letter-spacing: 0.05pt">l</FONT>icable continued l<FONT STYLE="letter-spacing: 0.05pt">i</FONT>sting
requirements of Nasdaq, our Common Stock could be de<FONT STYLE="letter-spacing: 0.05pt">l</FONT>isted, and we and our stockholders could
face s<FONT STYLE="letter-spacing: 0.05pt">i</FONT>gnificant mater<FONT STYLE="letter-spacing: 0.05pt">i</FONT>al adverse consequen<FONT STYLE="letter-spacing: 0.05pt">c</FONT>es.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In order to r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>main
listed on Nasd<FONT STYLE="letter-spacing: 0.05pt">a</FONT>q, we must satisfy minimum financial and other continued listing requiremen<FONT STYLE="letter-spacing: 0.05pt">t</FONT>s
and standards, including those regarding dire<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tor indep<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ndence
and independent commit<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ee requ<FONT STYLE="letter-spacing: 0.05pt">i</FONT>rements, <FONT STYLE="letter-spacing: 0.05pt">m</FONT>inimum
s<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ockholders&rsquo; equit<FONT STYLE="letter-spacing: -0.5pt">y</FONT>, mini<FONT STYLE="letter-spacing: 0.05pt">m</FONT>um
share price, and cer<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ain corpora<FONT STYLE="letter-spacing: 0.05pt">t</FONT>e governance
requiremen<FONT STYLE="letter-spacing: 0.05pt">t</FONT>s.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As of November 4, 2025, the
Company has rega<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ned compl<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ance wi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>h
the Minimum Bid Price <FONT STYLE="letter-spacing: 0.05pt">R</FONT>equirement and the Annual Meeting Requirement. <FONT STYLE="letter-spacing: -0.65pt">W</FONT>e
cannot assure you that we wi<FONT STYLE="letter-spacing: 0.05pt">l</FONT>l be able <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o continue
to <FONT STYLE="letter-spacing: 0.05pt">c</FONT>omply with the applicable listing stand<FONT STYLE="letter-spacing: 0.05pt">a</FONT>rds.
If we are not <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ble to comp<FONT STYLE="letter-spacing: 0.05pt">l</FONT>y with applic<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ble
listing standards, our shares of Common Stock will be subject to del<FONT STYLE="letter-spacing: 0.05pt">i</FONT>sting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">If N<FONT STYLE="letter-spacing: 0.05pt">a</FONT>sdaq
d<FONT STYLE="letter-spacing: 0.05pt">e</FONT>lists our Common Stock from trading on its exch<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nge
for fa<FONT STYLE="letter-spacing: 0.05pt">i</FONT>lure to meet comply wi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>h the <FONT STYLE="letter-spacing: 0.05pt">B</FONT>id
Price Rule, or any other list<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng s<FONT STYLE="letter-spacing: 0.05pt">t</FONT>andards, we
and our stockholders could fa<FONT STYLE="letter-spacing: 0.05pt">c</FONT>e significant m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>terial
adverse consequences inc<FONT STYLE="letter-spacing: 0.05pt">l</FONT>uding, but not limit<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
<TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a limited <FONT STYLE="letter-spacing: 0.05pt">a</FONT>vailabili<FONT STYLE="letter-spacing: 0.05pt">t</FONT>y
of market quotations for our se<FONT STYLE="letter-spacing: 0.05pt">c</FONT>urities;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a reduction in liqu<FONT STYLE="letter-spacing: 0.05pt">i</FONT>dity and market pri<FONT STYLE="letter-spacing: 0.05pt">c</FONT>e
of our Common Stock;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a reduction in the number of investors wi<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ling
to hold or <FONT STYLE="letter-spacing: 0.05pt">a</FONT>cquire our Common Stock, which could neg<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tively
impact our ab<FONT STYLE="letter-spacing: 0.05pt">i</FONT>lity to raise equi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>y financing;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a determina<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ion that our Co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>mon
Stock is a <FONT STYLE="letter-spacing: 0.05pt">&ldquo;</FONT>penny stock,&rdquo; which <FONT STYLE="letter-spacing: 0.05pt">w</FONT>ill
require brokers trading in our Com<FONT STYLE="letter-spacing: 0.05pt">m</FONT>on Stock to adhere to more stringent rules, possibly resulting
in a r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>duced level of trad<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng activity in the
secondary trading mark<FONT STYLE="letter-spacing: 0.05pt">e</FONT>t for our Common Stock;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a limited <FONT STYLE="letter-spacing: 0.05pt">a</FONT>mount of analyst coverag<FONT STYLE="letter-spacing: 0.05pt">e</FONT>;
and</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a decreased abi<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ity to issue addi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ional
securit<FONT STYLE="letter-spacing: 0.05pt">i</FONT>es or obtain addition<FONT STYLE="letter-spacing: 0.05pt">a</FONT>l financing in
the fu<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ure.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 16.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.65pt"><B><I>W</I></B></FONT><B><I>e
will have broad discret<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on in the use of the net proceeds from this o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering
and may not use them e<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fectivel<FONT STYLE="letter-spacing: -0.3pt">y</FONT>.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.7pt">W</FONT>e
currently in<FONT STYLE="letter-spacing: 0.05pt">t</FONT>end to use the net proceeds from the o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering
of <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he Common S<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ock under this prospectus suppl<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ment
for gen<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ral corporate purposes, including working capita<FONT STYLE="letter-spacing: 0.05pt">l</FONT>,
operating expenses, <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd capit<FONT STYLE="letter-spacing: 0.05pt">a</FONT>l expendi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ures,
as described <FONT STYLE="letter-spacing: 0.05pt">i</FONT>n the section of this prosp<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ctus
supplem<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nt enti<FONT STYLE="letter-spacing: 0.05pt">t</FONT>led &ldquo;<I>Use of <FONT STYLE="letter-spacing: 0.05pt">P</FONT><FONT STYLE="letter-spacing: -0.3pt">r</FONT>oceeds</I>.&rdquo;
<FONT STYLE="letter-spacing: -0.7pt">W</FONT>e <FONT STYLE="letter-spacing: 0.05pt">w</FONT>ill have bro<FONT STYLE="letter-spacing: 0.05pt">a</FONT>d
discretion <FONT STYLE="letter-spacing: 0.05pt">i</FONT>n the appli<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ation of the net proceeds
<FONT STYLE="letter-spacing: 0.05pt">i</FONT>n the ca<FONT STYLE="letter-spacing: 0.05pt">t</FONT>egory of general corporate purposes
and investors will be relying on <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he judgment of our management regard<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng
the applicat<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on of the proceeds of this o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The precise amount and timing
of the appli<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ation of these proceeds, if an<FONT STYLE="letter-spacing: -0.55pt">y</FONT>,
will depend upon a number of factors, such as our fund<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng requ<FONT STYLE="letter-spacing: 0.05pt">i</FONT>rements
and the availab<FONT STYLE="letter-spacing: 0.05pt">i</FONT>lity and costs of other funds. As of the da<FONT STYLE="letter-spacing: 0.05pt">t</FONT>e
of this prospectus supple<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ent, we cannot specify w<FONT STYLE="letter-spacing: 0.05pt">i</FONT>th
certainty a<FONT STYLE="letter-spacing: 0.05pt">l</FONT>l of the particul<FONT STYLE="letter-spacing: 0.05pt">a</FONT>r uses for the net
proceeds to us from this o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering. Depending on the outcome of our e<FONT STYLE="letter-spacing: -0.1pt">f</FONT>forts
and other unforeseen even<FONT STYLE="letter-spacing: 0.05pt">t</FONT>s, our plans <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd priorities
may change and we m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>y apply the net proceeds of th<FONT STYLE="letter-spacing: 0.05pt">i</FONT>s
o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fering in di<FONT STYLE="letter-spacing: -0.15pt">f</FONT>ferent manners than we curr<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ntly
anticip<FONT STYLE="letter-spacing: 0.05pt">a</FONT>te.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The failure by our management
<FONT STYLE="letter-spacing: 0.05pt">t</FONT>o apply these funds <FONT STYLE="letter-spacing: 0.05pt">e</FONT><FONT STYLE="letter-spacing: -0.15pt">f</FONT>fectively
could h<FONT STYLE="letter-spacing: 0.05pt">a</FONT>rm our business, finan<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ial condit<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on
and results of oper<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tions. Pending their use, we may invest the net proce<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ds
from this o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering in short-t<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rm, interest-b<FONT STYLE="letter-spacing: 0.05pt">e</FONT>aring
instruments. These investments <FONT STYLE="letter-spacing: 0.05pt">m</FONT>ay not yield a favorable return to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The actual number of shares we will issue under
the Sales Agreement, at any one time or in total, is uncertain. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Subject to certain limitations
in the Sales Agreement and compliance with applicable law, we have the discretion to deliver a placement notice to the sales agents at
any time throughout the term of the Sales Agreement. The number of shares that are sold by the sales agents after delivering a placement
notice will fluctuate based on the market price of our Common Stock during the sales period and limits we set with the sales agents. Because
the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not
possible at this stage to predict the number of shares that will be ultimately issued or the aggregate proceeds to be raised in connection
with sales under the Sales Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The Common Stock o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fered
hereby will be sold in &ldquo;at the market&rdquo; o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>ferings, and investors who buy shares
at di<FONT STYLE="letter-spacing: -0.1pt">f</FONT>ferent times will l<FONT STYLE="letter-spacing: 0.05pt">i</FONT>kely pay di<FONT STYLE="letter-spacing: -0.1pt">f</FONT>ferent
prices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Investors who purch<FONT STYLE="letter-spacing: 0.05pt">a</FONT>se
shares in this o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fering at d<FONT STYLE="letter-spacing: 0.05pt">i</FONT><FONT STYLE="letter-spacing: -0.15pt">f</FONT>ferent
tim<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s will likely p<FONT STYLE="letter-spacing: 0.05pt">a</FONT>y di<FONT STYLE="letter-spacing: -0.1pt">f</FONT>ferent
pri<FONT STYLE="letter-spacing: 0.05pt">c</FONT>es, and so may <FONT STYLE="letter-spacing: 0.05pt">e</FONT>xperience d<FONT STYLE="letter-spacing: 0.05pt">i</FONT><FONT STYLE="letter-spacing: -0.15pt">f</FONT>ferent
outcomes in the<FONT STYLE="letter-spacing: 0.05pt">i</FONT>r investment resul<FONT STYLE="letter-spacing: 0.05pt">t</FONT>s. <FONT STYLE="letter-spacing: -0.65pt">W</FONT>e
will have d<FONT STYLE="letter-spacing: 0.05pt">i</FONT>scretion, subject <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o market demand,
to vary the <FONT STYLE="letter-spacing: 0.05pt">t</FONT>iming, prices, and numbers of shares sold, and th<FONT STYLE="letter-spacing: 0.05pt">e</FONT>re
is no maximum sal<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s price. Pursu<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nt to the Sales
Agreement, our board of directors, or a duly <FONT STYLE="letter-spacing: 0.05pt">a</FONT>uthorized executive commit<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ee
<FONT STYLE="letter-spacing: 0.05pt">t</FONT>hereof, m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>y authori<FONT STYLE="letter-spacing: 0.05pt">z</FONT>e,
from time to time, a <FONT STYLE="letter-spacing: 0.05pt">m</FONT>inimum sales price per share of our Com<FONT STYLE="letter-spacing: 0.05pt">m</FONT>on
Stock sold in this o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering, which will limit our abili<FONT STYLE="letter-spacing: 0.05pt">t</FONT>y
to make sales <FONT STYLE="letter-spacing: 0.05pt">i</FONT>f the pri<FONT STYLE="letter-spacing: 0.05pt">c</FONT>e goes b<FONT STYLE="letter-spacing: 0.05pt">e</FONT>low
that minimum. Inves<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ors may experience a de<FONT STYLE="letter-spacing: 0.05pt">c</FONT>line
in the va<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ue of their shares as a r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>sult of share
sales <FONT STYLE="letter-spacing: 0.05pt">m</FONT>ade at prices <FONT STYLE="letter-spacing: 0.05pt">l</FONT>ower than the prices <FONT STYLE="letter-spacing: 0.05pt">t</FONT>hey
paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.65pt"><B><I>W</I></B></FONT><B><I>e
<FONT STYLE="letter-spacing: 0.05pt">w</FONT>ill need to raise substan<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ial additional capital
in the future <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o fund our operations and you may expe<FONT STYLE="letter-spacing: 0.05pt">r</FONT>ience
further dilution if we issue additional equity securi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ies in future fundraising <FONT STYLE="letter-spacing: 0.05pt">t</FONT>ransactions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.7pt">W</FONT>e
will need to r<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ise substantial additional <FONT STYLE="letter-spacing: 0.05pt">c</FONT>apital
in the future to fund our oper<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tions. <FONT STYLE="letter-spacing: -0.65pt">T</FONT>o raise
additional <FONT STYLE="letter-spacing: 0.05pt">c</FONT>apital, we <FONT STYLE="letter-spacing: 0.05pt">m</FONT>ay in the future o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fer
additional shares of our Common Sto<FONT STYLE="letter-spacing: 0.05pt">c</FONT>k or other securi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ies
convertible into or exchang<FONT STYLE="letter-spacing: 0.05pt">e</FONT>able for our Com<FONT STYLE="letter-spacing: 0.05pt">m</FONT>on
Sto<FONT STYLE="letter-spacing: 0.05pt">c</FONT>k <FONT STYLE="letter-spacing: 0.05pt">a</FONT>t pr<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ces
that may not be the same as the price per share in this o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering. <FONT STYLE="letter-spacing: -0.7pt">W</FONT>e
may sell shares or o<FONT STYLE="letter-spacing: 0.05pt">t</FONT>her securi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ies in any other
o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fering at a price per share that <FONT STYLE="letter-spacing: 0.05pt">i</FONT>s less <FONT STYLE="letter-spacing: 0.05pt">t</FONT>han
the price per share pa<FONT STYLE="letter-spacing: 0.05pt">i</FONT>d by inves<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ors in th<FONT STYLE="letter-spacing: 0.05pt">i</FONT>s
o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fering, and inves<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ors purchasing sh<FONT STYLE="letter-spacing: 0.05pt">a</FONT>res
or oth<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r securiti<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s in <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he
future <FONT STYLE="letter-spacing: 0.05pt">c</FONT>ould have rights superior to exist<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng
stockholders. The price per share at which we sell additional sh<FONT STYLE="letter-spacing: 0.05pt">a</FONT>res of our Co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>mon
Stock, or securities conver<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ible or exchangeable <FONT STYLE="letter-spacing: 0.05pt">i</FONT>nto
Common Stock, in future transa<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tions may be higher or lower than the price per share p<FONT STYLE="letter-spacing: 0.05pt">a</FONT>id
by investors in this o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fering. Furthe<FONT STYLE="letter-spacing: -0.3pt">r</FONT>, the ex<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rcise
of ou<FONT STYLE="letter-spacing: 0.05pt">t</FONT>standing stock options and warr<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nts may
r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>sult in furth<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r dilution of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>




<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><B><A NAME="a_006"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 246.3pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.7pt">W</FONT>e
may issue and se<FONT STYLE="letter-spacing: 0.05pt">l</FONT>l shares of Common Stock having aggregate sales proc<FONT STYLE="letter-spacing: 0.05pt">e</FONT>eds
of up to $11,702,826 from time <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o time, before deduc<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ing
sales agent commissions and estimat<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d exp<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nses
p<FONT STYLE="letter-spacing: 0.05pt">a</FONT>yable by us. The amount of proceeds from <FONT STYLE="letter-spacing: 0.05pt">t</FONT>his
o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering will dep<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nd upon the number of <FONT STYLE="letter-spacing: 0.05pt">s</FONT>hares
of our Common Stock sold and the market pr<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ce at which th<FONT STYLE="letter-spacing: 0.05pt">e</FONT>y
are sold. There can be no assur<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nce that we wi<FONT STYLE="letter-spacing: 0.05pt">l</FONT>l
be able to se<FONT STYLE="letter-spacing: 0.05pt">l</FONT>l any shares under or fully ut<FONT STYLE="letter-spacing: 0.05pt">i</FONT>lize
the Sa<FONT STYLE="letter-spacing: 0.05pt">l</FONT>es Agreement with Dawson J<FONT STYLE="letter-spacing: 0.05pt">a</FONT>mes as a source
of financing. <FONT STYLE="letter-spacing: -0.65pt">W</FONT>e will retain bro<FONT STYLE="letter-spacing: 0.05pt">a</FONT>d discretion
over the use of the net proceeds from the s<FONT STYLE="letter-spacing: 0.05pt">a</FONT>le of the Common S<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ock
o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fered by this prospec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>us supplement and the
a<FONT STYLE="letter-spacing: 0.05pt">c</FONT>companying prospe<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tus. <FONT STYLE="letter-spacing: -0.65pt">W</FONT>e
current<FONT STYLE="letter-spacing: 0.05pt">l</FONT>y intend to use the net proc<FONT STYLE="letter-spacing: 0.05pt">e</FONT>eds, if
an<FONT STYLE="letter-spacing: -0.55pt">y</FONT>, from the sale of the Common <FONT STYLE="letter-spacing: 0.05pt">S</FONT>tock o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fered
hereby for gener<FONT STYLE="letter-spacing: 0.05pt">a</FONT>l corporate purposes, including working capital, opera<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ing
expenses, and capital expendi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ures. <FONT STYLE="letter-spacing: -0.65pt">W</FONT>e may also
use a portion of the net proceeds to a<FONT STYLE="letter-spacing: 0.05pt">c</FONT>quire or inve<FONT STYLE="letter-spacing: 0.05pt">s</FONT>t
<FONT STYLE="letter-spacing: 0.05pt">i</FONT>n business<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s and products that are comp<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ementary
to our own, although we have no current plans, commitmen<FONT STYLE="letter-spacing: 0.05pt">t</FONT>s or agreem<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nts
w<FONT STYLE="letter-spacing: 0.05pt">i</FONT>th respect to any acquis<FONT STYLE="letter-spacing: 0.05pt">i</FONT>tions as of the date
of th<FONT STYLE="letter-spacing: 0.05pt">i</FONT>s prosp<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ctus supplement. <FONT STYLE="letter-spacing: -0.65pt">W</FONT>e
intend to invest <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he net proceeds to us from the s<FONT STYLE="letter-spacing: 0.05pt">a</FONT>le
of the Common Stock o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fered hereby that are not us<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d
as described above in short-<FONT STYLE="letter-spacing: 0.05pt">t</FONT>erm, investment-gr<FONT STYLE="letter-spacing: 0.05pt">a</FONT>de,
interest-be<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ring instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>




<P STYLE="margin: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><B><A NAME="a_007"></A>DIVIDEND POLICY</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.7pt">We
</FONT>have never paid any cash dividends on our cap<FONT STYLE="letter-spacing: 0.05pt">i</FONT>tal sto<FONT STYLE="letter-spacing: 0.05pt">c</FONT>k
and do not anticip<FONT STYLE="letter-spacing: 0.05pt">a</FONT>te paying any cash dividends on our Common Sto<FONT STYLE="letter-spacing: 0.05pt">c</FONT>k
in the foreseeable future. <FONT STYLE="letter-spacing: -0.65pt">W</FONT>e <FONT STYLE="letter-spacing: 0.05pt">i</FONT>ntend to reta<FONT STYLE="letter-spacing: 0.05pt">i</FONT>n
future earnings to fund ongoing op<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rations <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd
future capit<FONT STYLE="letter-spacing: 0.05pt">a</FONT>l requir<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ments. Any future determin<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tion
to pay cash d<FONT STYLE="letter-spacing: 0.05pt">i</FONT>vidends wi<FONT STYLE="letter-spacing: 0.05pt">l</FONT>l be at the discre<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ion
of our board of directors and will be dependent upon a number of fa<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tors, including future
e<FONT STYLE="letter-spacing: 0.05pt">a</FONT>rnings, our f<FONT STYLE="letter-spacing: 0.05pt">i</FONT>nancial condi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ion,
results of operations, capit<FONT STYLE="letter-spacing: 0.05pt">a</FONT>l requirements <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd
such other factors as the bo<FONT STYLE="letter-spacing: 0.05pt">a</FONT>rd of directors deems re<FONT STYLE="letter-spacing: 0.05pt">l</FONT>evant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B><A NAME="a_008"></A>DILUTION<FONT STYLE="line-height: 107%"><SUP></SUP></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 265.15pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">If you purchase our Common Stock
in th<FONT STYLE="letter-spacing: 0.05pt">i</FONT>s o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering, your ownership interest will
be immedi<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tely d<FONT STYLE="letter-spacing: 0.05pt">i</FONT>luted <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o
the extent of the d<FONT STYLE="letter-spacing: 0.05pt">i</FONT><FONT STYLE="letter-spacing: -0.15pt">f</FONT>ference be<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ween
<FONT STYLE="letter-spacing: 0.05pt">t</FONT>he price per share you pay and the net t<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ngible
book va<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ue p<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r sh<FONT STYLE="letter-spacing: 0.05pt">a</FONT>re
of our Common Stock imm<FONT STYLE="letter-spacing: 0.05pt">e</FONT>diately after this o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering.
Net tangible book value per share is determined by dividing <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he number of shares of Common
Sto<FONT STYLE="letter-spacing: 0.05pt">c</FONT>k outstanding as of September 30, 2025 by our total tangible <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ssets
less total liabili<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our net tangib<FONT STYLE="letter-spacing: 0.05pt">l</FONT>e
book value as of <FONT STYLE="letter-spacing: 0.15pt">September 30, 2025 </FONT>was approximately $(19.2) million, or $(0.83) per share,
b<FONT STYLE="letter-spacing: 0.05pt">a</FONT>sed on <FONT STYLE="letter-spacing: 0.15pt">23,178,116 of o</FONT>ur Common Stock outstanding
as of that date.*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">After giv<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng e<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fect
to <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he sa<FONT STYLE="letter-spacing: 0.05pt">l</FONT>e of 8,933,455 shares of Co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>mon
Stock by us at an <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ssumed o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering price of $1.31
per share, the last reported <FONT STYLE="letter-spacing: 0.05pt">s</FONT>ale pr<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ce of our
Common Sto<FONT STYLE="letter-spacing: 0.05pt">c</FONT>k on Nasdaq on <FONT STYLE="letter-spacing: 0.15pt">December 1, 2025</FONT>, for
aggregate gross proceeds of $11,702,826, <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd after dedu<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ting
the s<FONT STYLE="letter-spacing: 0.05pt">a</FONT>les comm<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ssions and est<FONT STYLE="letter-spacing: 0.05pt">i</FONT>mated
expenses pay<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ble by us, our as ad<FONT STYLE="letter-spacing: 0.05pt">j</FONT>usted net tangib<FONT STYLE="letter-spacing: 0.05pt">l</FONT>e
book value <FONT STYLE="letter-spacing: 0.05pt">a</FONT>s of <FONT STYLE="letter-spacing: 0.5pt">December 1, 2025</FONT> would have been
<FONT STYLE="letter-spacing: 0.05pt">a</FONT>pproximately ($7.49) million, or ($0.23) per share. This represents an im<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ediate
<FONT STYLE="letter-spacing: 0.6pt">increase </FONT>in net tangible book va<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ue of $0.59 per
share <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o existing stockholders and <FONT STYLE="letter-spacing: 0.05pt">a</FONT>n <FONT STYLE="letter-spacing: 0.05pt">i</FONT>mmediate
decrease in net tang<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ble book value of $1.54 per share to new inves<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ors
in this o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The fol<FONT STYLE="letter-spacing: 0.05pt">l</FONT>owing tab<FONT STYLE="letter-spacing: 0.05pt">l</FONT>e
il<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ustrates this <FONT STYLE="letter-spacing: 0.05pt">c</FONT>alculat<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on
on a per share basis. The as adjusted information is <FONT STYLE="letter-spacing: 0.05pt">i</FONT>llustrative only and wi<FONT STYLE="letter-spacing: 0.05pt">l</FONT>l
ch<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nge based on <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he a<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tual
price to the publi<FONT STYLE="letter-spacing: 0.05pt">c</FONT>, the <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ctual nu<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ber
of shares sold and other t<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rms of the o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering
deter<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ined at the t<FONT STYLE="letter-spacing: 0.05pt">i</FONT>me shares of our Co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>mon
Stock <FONT STYLE="letter-spacing: 0.05pt">a</FONT>re sold pursu<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nt to this prospectus supplement.
The as adjusted inform<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tion assumes that all of our Common Stock in the aggreg<FONT STYLE="letter-spacing: 0.05pt">a</FONT>te
amount of $11,702,826 is sold at the assu<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ed o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fering
price of $1.31 per share, the l<FONT STYLE="letter-spacing: 0.05pt">a</FONT>st repor<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ed sa<FONT STYLE="letter-spacing: 0.05pt">l</FONT>e
price of our Co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>mon Stock on Nasdaq on <FONT STYLE="letter-spacing: 0.4pt">December 1, 2025</FONT>.
The shares sold in this o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering, if an<FONT STYLE="letter-spacing: -0.55pt">y</FONT>, will
be sold from ti<FONT STYLE="letter-spacing: 0.05pt">m</FONT>e to time at various prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Offering price per share</TD><TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">1.31</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0pt; padding-left: 0pt">Net tangible book value per share as of September 30, 2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.83</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0pt; padding-left: 0pt">Increase in net tangible book value per share attributable to this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.59</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0pt; padding-left: 0pt">As adjusted net tangible book value per share after giving effect to this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.23</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0pt; padding-left: 0pt">Decrease in net tangible book value per share to new investors in this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1.54</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.45in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="text-indent: 36pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The above table <FONT STYLE="letter-spacing: 0.05pt">i</FONT>s
based on 23,178,116 shares of Common Stock outst<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nding as of September 30, 2025, and exc<FONT STYLE="letter-spacing: 0.05pt">l</FONT>udes
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.45in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
<TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">267,695 shares of Common Stock issuable in connection with the acquisition of Renovaro Cube
as contingent consideration;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">626,983 shares of Common Stock issuable upon the exercise of warrants at a weighted average
exercise prices of $9.09 per share;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
<TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">350,210 shares of Common Stock issuable upon the exercise of options at a weighted average
exercise price of $7.21 per share.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.6pt; text-align: justify; text-indent: -35.1pt">&nbsp;</P>

<P STYLE="text-indent: 36pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">* On July
7, 2025, the Company converted $16.1 million in convertible promissory notes into an aggregate of 5.36 million shares of Common Stock,
based on the state $3.00 per share conversion price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Unless otherwise indicat<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d,
a<FONT STYLE="letter-spacing: 0.05pt">l</FONT>l information in this prospectus reflec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>s the
<FONT STYLE="letter-spacing: 0.05pt">R</FONT>everse Stock Split and assumes no issuance of the outstanding contingent consideration described
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>




<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B><A NAME="a_009"></A>DESCRIPTION OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 221.05pt"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">In this o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fering,
we are o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering shares of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.45in">&nbsp;</P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt"><B>Authorized Capital Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">Our authoriz<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d
capi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>al sto<FONT STYLE="letter-spacing: 0.05pt">c</FONT>k consists of 350,000,000 shares of
Common Stock, p<FONT STYLE="letter-spacing: 0.05pt">a</FONT>r value $0.0001 per share. As of the date of this prospectus, we had 23,430,653
shares of Common Sto<FONT STYLE="letter-spacing: 0.05pt">c</FONT>k outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="letter-spacing: -0.95pt"><I>V</I></FONT><I>oting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">For a<FONT STYLE="letter-spacing: 0.05pt">l</FONT>l
matters submi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ted to a vote of stockholders, each holder of Common Stock is en<FONT STYLE="letter-spacing: 0.05pt">t</FONT>itled
to one vote for each share regis<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ered in his or h<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r
n<FONT STYLE="letter-spacing: 0.05pt">a</FONT>me on our books. Our Common Stock do<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s not h<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ve
cumul<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tive vo<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ing rights. As a result, holders
of a ma<FONT STYLE="letter-spacing: 0.05pt">j</FONT>ority of our outstanding Common Stock c<FONT STYLE="letter-spacing: 0.05pt">a</FONT>n
elect all of the directors who are up for e<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ection in a part<FONT STYLE="letter-spacing: 0.05pt">i</FONT>cular
yea<FONT STYLE="letter-spacing: -0.45pt">r</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Dividends</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each stockholder is entitled to
receive the dividends as may be declared by our board of directors out of funds legally available for dividends. Our board of directors
is not obligated to declare a dividend. Any future dividends will be subject to the discretion of our board of directors and will depend
upon, among other things, future earnings, the operating and financial condition of our Company, its capital requirements, general business
conditions and other pertinent factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Liquidation and Dissolution</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each stockholder is entitled in
the event of liquidation, to share pro rata in any distribution of our assets after payment of liabilities, subject to the rights and
preferences of the holders of any outstanding shares of any series of our preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Other Rights and Restr<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ctions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Holders of our Com<FONT STYLE="letter-spacing: 0.05pt">m</FONT>on
Stock do not have preemptive or subs<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ription righ<FONT STYLE="letter-spacing: 0.05pt">t</FONT>s,
and they h<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ve no right <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o convert their Common
Stock <FONT STYLE="letter-spacing: 0.05pt">i</FONT>nto any other securities. Our <FONT STYLE="letter-spacing: 0.05pt">C</FONT>ommon Stock
is not subj<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ct <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o redemp<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ion
by us. The rights, preferences and priv<FONT STYLE="letter-spacing: 0.05pt">i</FONT>leges of common stockholders are subject to <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he
rights of <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he stockholders of any s<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ries of Preferred
S<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ock which we m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>y designa<FONT STYLE="letter-spacing: 0.05pt">t</FONT>e
in the futur<FONT STYLE="letter-spacing: 0.05pt">e</FONT>. Our <FONT STYLE="letter-spacing: 0.05pt">C</FONT>ertificate of In<FONT STYLE="letter-spacing: 0.05pt">c</FONT>orporation
and our Byl<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ws do not restri<FONT STYLE="letter-spacing: 0.05pt">c</FONT>t the ability of
a holder of Common Stock to tr<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nsfer his or her shares of Common Sto<FONT STYLE="letter-spacing: 0.05pt">c</FONT>k.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Market, Symbol and <FONT STYLE="letter-spacing: -0.45pt">T</FONT>ransfer
Agent</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our Common Stock is listed for
trading on the <FONT STYLE="letter-spacing: 0.05pt">N</FONT>asdaq Cap<FONT STYLE="letter-spacing: 0.05pt">i</FONT>tal Mark<FONT STYLE="letter-spacing: 0.05pt">e</FONT>t
under <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he symbol &ldquo;LNAI&rdquo;. The transfer agent and registrar for our Co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>mon
Stock is Securities Transfer Corporation, and its address is 2901 N. Dallas Parkway, Suite 380, Plano, TX 75093.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>




<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B><A NAME="a_010"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 234.05pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.7pt">W</FONT>e
have entered into a Sales Agreement with Dawson James, pursuant to <FONT STYLE="letter-spacing: 0.05pt">w</FONT>hich we may issue and
sell from time to time, shares of our Common Stock having an aggrega<FONT STYLE="letter-spacing: 0.05pt">t</FONT>e o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering
pri<FONT STYLE="letter-spacing: 0.05pt">c</FONT>e of up to $11,702,826 through Dawson Jam<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s
as our sales agent. The Common Sto<FONT STYLE="letter-spacing: 0.05pt">c</FONT>k may be o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fered
and sold by any method permitted by law deemed to be an &ldquo;at the market&rdquo; offering as defined in Rule 415 under the Securities
Act, including without limitation sales made directly on the Exchange, on any other existing trading market for the Common Stock or to
or through a market maker. Dawson James may also sell the Common Stock by any other method permitted by law, including but not limited
to in negotiated transactions with the Company&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Dawson J<FONT STYLE="letter-spacing: 0.05pt">a</FONT>mes
will o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fer shar<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s of our Common Stock at prevailing
market pri<FONT STYLE="letter-spacing: 0.05pt">c</FONT>es subject to the terms and conditions of the Sales Agreement as agreed upon by
us and Dawson J<FONT STYLE="letter-spacing: 0.05pt">a</FONT>mes. <FONT STYLE="letter-spacing: -0.65pt">W</FONT>e will designate the numb<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r
of shares which we desire to sell, the time period during which sales are request<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d to be
made, any lim<FONT STYLE="letter-spacing: 0.05pt">i</FONT>tation on the number of sh<FONT STYLE="letter-spacing: 0.05pt">a</FONT>res that
may be sold in one day and any min<FONT STYLE="letter-spacing: 0.05pt">i</FONT>mum price below wh<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ch
sales may not be made. Subject to the terms <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd conditions of the Sa<FONT STYLE="letter-spacing: 0.05pt">l</FONT>es
Agreement, Dawson J<FONT STYLE="letter-spacing: 0.05pt">a</FONT>mes will use <FONT STYLE="letter-spacing: 0.05pt">i</FONT>ts <FONT STYLE="letter-spacing: 0.05pt">c</FONT>ommercial<FONT STYLE="letter-spacing: 0.05pt">l</FONT>y
re<FONT STYLE="letter-spacing: 0.05pt">a</FONT>sonable e<FONT STYLE="letter-spacing: -0.15pt">f</FONT>forts consis<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ent
with <FONT STYLE="letter-spacing: 0.05pt">i</FONT>ts nor<FONT STYLE="letter-spacing: 0.05pt">m</FONT>al <FONT STYLE="letter-spacing: 0.05pt">t</FONT>rading
<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd sa<FONT STYLE="letter-spacing: 0.05pt">l</FONT>es pr<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ctices
to sell on our beha<FONT STYLE="letter-spacing: 0.05pt">l</FONT>f <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ll of <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he
sh<FONT STYLE="letter-spacing: 0.05pt">a</FONT>res r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>quested to be sold by us. <FONT STYLE="letter-spacing: -0.65pt">W</FONT><FONT STYLE="letter-spacing: -0.05pt">e</FONT>
or Dawson Jam<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>y suspend the o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering
of the shares of Common Stock being made through Dawson James under the Sa<FONT STYLE="letter-spacing: 0.05pt">l</FONT>e<FONT STYLE="letter-spacing: 1.75pt">s</FONT>Agreement
upon proper noti<FONT STYLE="letter-spacing: 0.05pt">c</FONT>e to the other part<FONT STYLE="letter-spacing: -0.5pt">y</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Settlement for sal<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s
of Co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>mon Stock w<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ll occur on the second trad<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng
day fol<FONT STYLE="letter-spacing: 0.05pt">l</FONT>owing the date on which any sales are made, or on some other da<FONT STYLE="letter-spacing: 0.05pt">t</FONT>e
that is agreed upon by us and <FONT STYLE="letter-spacing: 0.05pt">D</FONT>awson Jam<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s in
connection with a par<FONT STYLE="letter-spacing: 0.05pt">t</FONT>icular transaction, in r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>turn
for payment of the net proceeds to us. Sales of our shares of our Common Sto<FONT STYLE="letter-spacing: 0.05pt">c</FONT>k as contempl<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ted
in this prospectus supplement and the acco<FONT STYLE="letter-spacing: 0.05pt">m</FONT>panying prospec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>us
will be settled through <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he fac<FONT STYLE="letter-spacing: 0.05pt">i</FONT>lities of The
Depository <FONT STYLE="letter-spacing: -0.25pt">T</FONT>rust Company or by such oth<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r means
as we and Dawson James m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>y agree upon. There is no arrang<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ment
for funds to be received in an escro<FONT STYLE="letter-spacing: -0.55pt">w</FONT>, trust or similar arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.7pt">W</FONT>e
wi<FONT STYLE="letter-spacing: 0.05pt">l</FONT>l pay Dawson James in c<FONT STYLE="letter-spacing: 0.05pt">a</FONT>sh, upon <FONT STYLE="letter-spacing: 0.05pt">e</FONT>ach
sale of shares of our Com<FONT STYLE="letter-spacing: 0.05pt">m</FONT>on Stock pursuant to the Sal<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s
Agreement, a co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>mission of 3.0% of the gross proceeds from each sale of shares. <FONT STYLE="letter-spacing: 0.05pt">B</FONT>ecause
there is no min<FONT STYLE="letter-spacing: 0.05pt">i</FONT>mum o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering amount required as
a <FONT STYLE="letter-spacing: 0.05pt">c</FONT>ondition to th<FONT STYLE="letter-spacing: 0.05pt">i</FONT>s o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering,
the actual total public o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering amount, sales co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>missions
and proce<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ds to us, if an<FONT STYLE="letter-spacing: -0.55pt">y</FONT>, <FONT STYLE="letter-spacing: 0.05pt">a</FONT>re
not determin<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ble at this time. Pursuant to <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he
terms of the Sales Agreement, we agreed to r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>imburse Dawson <FONT STYLE="letter-spacing: 0.05pt">J</FONT>ames
for its out-of-pocket expenses (including but not limited to the reasonable and documented fees and expenses of i<FONT STYLE="letter-spacing: 0.05pt">t</FONT>s
<FONT STYLE="letter-spacing: 0.05pt">l</FONT>egal counsel) reasonab<FONT STYLE="letter-spacing: 0.05pt">l</FONT>y <FONT STYLE="letter-spacing: 0.05pt">i</FONT>ncurred
in connection with ent<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ring into the transact<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ons
<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ontemplated by the Sales Agreement in an amount not to ex<FONT STYLE="letter-spacing: 0.05pt">c</FONT>eed
$50,000 in the aggrega<FONT STYLE="letter-spacing: 0.05pt">t</FONT>e, in <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ddition to up to
a maximum of $10,000 per ye<FONT STYLE="letter-spacing: 0.05pt">a</FONT>r for due di<FONT STYLE="letter-spacing: 0.05pt">l</FONT>igence
upda<FONT STYLE="letter-spacing: 0.05pt">t</FONT>e sessions conducted in <FONT STYLE="letter-spacing: 0.05pt">c</FONT>onnection wi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>h
each su<FONT STYLE="letter-spacing: 0.05pt">c</FONT>h date the Company fi<FONT STYLE="letter-spacing: 0.05pt">l</FONT>es its qu<FONT STYLE="letter-spacing: 0.05pt">a</FONT>rterly
reports on Form 10-Q and annual report on Form 10-K, for D<FONT STYLE="letter-spacing: 0.05pt">a</FONT>wson James counsel<FONT STYLE="letter-spacing: -0.45pt">&rsquo;</FONT>s
fees and any in<FONT STYLE="letter-spacing: 0.05pt">c</FONT>idental expenses to be reimbursed by us. <FONT STYLE="letter-spacing: -0.65pt">W</FONT>e
will report at least quart<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rly the numb<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r of shares
of our <FONT STYLE="letter-spacing: 0.05pt">C</FONT>ommon S<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ock so<FONT STYLE="letter-spacing: 0.05pt">l</FONT>d
through Dawson Ja<FONT STYLE="letter-spacing: 0.05pt">m</FONT>es under the Sales Agreement, the n<FONT STYLE="letter-spacing: 0.05pt">e</FONT>t
proc<FONT STYLE="letter-spacing: 0.05pt">e</FONT>eds <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o us and the compensation paid by us
to Dawson James in connection with the sales of shares of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.7pt">W</FONT>e
have agreed in the Sales Agreement to provide ind<FONT STYLE="letter-spacing: 0.05pt">e</FONT>mnification <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd
contribution to Dawson Jam<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s against cert<FONT STYLE="letter-spacing: 0.05pt">a</FONT>in liabili<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ies,
including l<FONT STYLE="letter-spacing: 0.05pt">i</FONT>abiliti<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s under the Securiti<FONT STYLE="letter-spacing: 0.05pt">e</FONT><FONT STYLE="letter-spacing: 1.75pt">s</FONT>Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fering
of our shares of our Com<FONT STYLE="letter-spacing: 0.05pt">m</FONT>on Sto<FONT STYLE="letter-spacing: 0.05pt">c</FONT>k pursuant to
the Sal<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s Agreement will term<FONT STYLE="letter-spacing: 0.05pt">i</FONT>nate upon <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he
<FONT STYLE="letter-spacing: 0.05pt">e</FONT>arlier of the sale of all of the shares of our Common Stock provided for in this prosp<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ctus
supplement or t<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rmination of the Sa<FONT STYLE="letter-spacing: 0.05pt">l</FONT>e<FONT STYLE="letter-spacing: 1.75pt">s</FONT>Agreement
as p<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rmitted ther<FONT STYLE="letter-spacing: 0.05pt">e</FONT>in.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.6pt">T</FONT>o
the extent required by R<FONT STYLE="letter-spacing: 0.05pt">e</FONT>gulation M, D<FONT STYLE="letter-spacing: 0.05pt">a</FONT>wson James
w<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ll not <FONT STYLE="letter-spacing: 0.05pt">e</FONT>ngage in any market <FONT STYLE="letter-spacing: 0.05pt">m</FONT>aking
act<FONT STYLE="letter-spacing: 0.05pt">i</FONT>vities involv<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng our Common Stock while the
o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fering is ongoing under this prospectus supplem<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">This prospectus supplement <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd
<FONT STYLE="letter-spacing: 0.05pt">t</FONT>he accompanying prospectus m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>y be <FONT STYLE="letter-spacing: 0.05pt">m</FONT>ade
available in electronic form<FONT STYLE="letter-spacing: 0.05pt">a</FONT>t on a <FONT STYLE="letter-spacing: 0.05pt">w</FONT>ebsite maint<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ined
by Dawson James, and Dawson James may dis<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ribute this prospectus supp<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ement
and the a<FONT STYLE="letter-spacing: 0.05pt">c</FONT>companying prospectus e<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ectronical<FONT STYLE="letter-spacing: 0.05pt">l</FONT><FONT STYLE="letter-spacing: -0.55pt">y</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The foregoing does not purport
to be a comp<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ete stat<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ment of the <FONT STYLE="letter-spacing: 0.05pt">t</FONT>erms
and condit<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ons of the Sales Agreement. A copy of the Sal<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s
Agreement <FONT STYLE="letter-spacing: 0.05pt">i</FONT>s included as an <FONT STYLE="letter-spacing: 0.05pt">e</FONT>xhibit to our Current
Report on Form 8-K th<FONT STYLE="letter-spacing: 0.05pt">a</FONT>t will be f<FONT STYLE="letter-spacing: 0.05pt">i</FONT>led with the
S<FONT STYLE="letter-spacing: 0.05pt">E</FONT>C and incorporat<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d by reference in<FONT STYLE="letter-spacing: 0.05pt">t</FONT>o
the registra<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ion statem<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nt of which this prosp<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ctus
supplement and the accompanying prospectus form a part. See &ldquo;<I>Whe<FONT STYLE="letter-spacing: -0.3pt">r</FONT>e <FONT STYLE="letter-spacing: -0.75pt">Y</FONT>ou
<FONT STYLE="letter-spacing: 0.05pt">C</FONT>an F<FONT STYLE="letter-spacing: 0.05pt">i</FONT>nd Mo<FONT STYLE="letter-spacing: -0.25pt">r</FONT>e
Infor<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ation</I>&rdquo; and <FONT STYLE="letter-spacing: 0.05pt">&ldquo;</FONT><I>Incorporation
of <FONT STYLE="letter-spacing: 0.05pt">C</FONT>ertain Information By Ref<FONT STYLE="letter-spacing: 0.05pt">e</FONT><FONT STYLE="letter-spacing: -0.3pt">r</FONT>ence</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-indent: 36pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Our Common Stock is lis<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ed
on Nasdaq under the symbol &ldquo;LNAI.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Other than in the United States,
no action has been taken by us or <FONT STYLE="letter-spacing: 0.05pt">D</FONT>awson James that wou<FONT STYLE="letter-spacing: 0.05pt">l</FONT>d
permit a public o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering of the se<FONT STYLE="letter-spacing: 0.05pt">c</FONT>urities o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fered
by this prospectus suppl<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ment <FONT STYLE="letter-spacing: 0.05pt">i</FONT>n any jurisdiction
where action for that purpose is requ<FONT STYLE="letter-spacing: 0.05pt">i</FONT>red. The securities o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fered
by this prospectus supp<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ement may not be o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fered
or sold, direct<FONT STYLE="letter-spacing: 0.05pt">l</FONT>y or indire<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tl<FONT STYLE="letter-spacing: -0.55pt">y</FONT>,
nor may th<FONT STYLE="letter-spacing: 0.05pt">i</FONT>s prospectus supp<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ement or any other
o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fering materi<FONT STYLE="letter-spacing: 0.05pt">a</FONT>l or adv<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rtisements
in connect<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on with <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fer
and sale of any such securiti<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s be distribut<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d
or published in <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ny jurisdiction, except under c<FONT STYLE="letter-spacing: 0.05pt">i</FONT>rcumstances
<FONT STYLE="letter-spacing: 0.05pt">t</FONT>hat will result in co<FONT STYLE="letter-spacing: 0.05pt">m</FONT>pliance wi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>h
the appli<FONT STYLE="letter-spacing: 0.05pt">c</FONT>able rules <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd regulations of that <FONT STYLE="letter-spacing: 0.05pt">j</FONT>urisdiction.
P<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rsons into whose possession <FONT STYLE="letter-spacing: 0.05pt">t</FONT>his prospectus
supplement comes are advised to inform <FONT STYLE="letter-spacing: 0.05pt">t</FONT>hemselves about and <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o
observe <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ny restrictions relat<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng to the o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fering
and the distribution of <FONT STYLE="letter-spacing: 0.05pt">t</FONT>his prospe<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tus supple<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ent.
This prospectus supplement does not constitute an o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fer to sell or a solicitat<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on
of an o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fer to buy any securities o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fered by
this prospectus supplement in any <FONT STYLE="letter-spacing: 0.05pt">j</FONT>urisdiction where <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ny
such o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fer or a solicitation <FONT STYLE="letter-spacing: 0.05pt">i</FONT>s unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Other Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Dawson James <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd
certain of its a<FONT STYLE="letter-spacing: -0.1pt">f</FONT>filiates have <FONT STYLE="letter-spacing: 0.05pt">e</FONT>ngaged in, and
<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ay in the future engage <FONT STYLE="letter-spacing: 0.05pt">i</FONT>n, investment banking
and oth<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r commerci<FONT STYLE="letter-spacing: 0.05pt">a</FONT>l dealings in the ordinary
course of business w<FONT STYLE="letter-spacing: 0.05pt">i</FONT>th us or our a<FONT STYLE="letter-spacing: -0.1pt">f</FONT>filiates.
Dawson Ja<FONT STYLE="letter-spacing: 0.05pt">m</FONT>es and <FONT STYLE="letter-spacing: 0.05pt">s</FONT>uch a<FONT STYLE="letter-spacing: -0.1pt">f</FONT>filiates
have r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ceived, or may in the future receive, customary fees and expenses for these transact<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ons.
In add<FONT STYLE="letter-spacing: 0.05pt">i</FONT>tion, in the ordin<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ry course of its various
busin<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ss act<FONT STYLE="letter-spacing: 0.05pt">i</FONT>vities, Dawson James and <FONT STYLE="letter-spacing: 0.05pt">i</FONT>ts
a<FONT STYLE="letter-spacing: -0.1pt">f</FONT>filiates m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>y make or hold a broad array of investments
and active<FONT STYLE="letter-spacing: 0.05pt">l</FONT>y trade debt and equity securi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ies
(or rel<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ted derivative securi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ies) <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd
fin<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ncial instruments (which may include bank loans) for <FONT STYLE="letter-spacing: 0.05pt">t</FONT>heir
own account and for the accounts of the<FONT STYLE="letter-spacing: 0.05pt">i</FONT>r customers. Such inv<FONT STYLE="letter-spacing: 0.05pt">e</FONT>stments
and se<FONT STYLE="letter-spacing: 0.05pt">c</FONT>urities ac<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ivities m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>y
involve securi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ies and/or instru<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ents of ours
or our a<FONT STYLE="letter-spacing: -0.15pt">f</FONT>filiates. Dawson Ja<FONT STYLE="letter-spacing: 0.05pt">m</FONT>es or its a<FONT STYLE="letter-spacing: -0.15pt">f</FONT>filiates
may <FONT STYLE="letter-spacing: 0.05pt">a</FONT>lso m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ke inves<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ment
r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>commendations and/or publish or express <FONT STYLE="letter-spacing: 0.05pt">i</FONT>ndependent
research views in respect of <FONT STYLE="letter-spacing: 0.05pt">s</FONT>uch securities or finan<FONT STYLE="letter-spacing: 0.05pt">c</FONT>ial
instrumen<FONT STYLE="letter-spacing: 0.05pt">t</FONT>s and may hold, or recommend <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o clients
that they acquire, long and/or short pos<FONT STYLE="letter-spacing: 0.05pt">i</FONT>tions in such securi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ies
and instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>




<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>LEGAL M<FONT STYLE="letter-spacing: -0.65pt"><A NAME="a_011"></A>A</FONT>TTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 249.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The val<FONT STYLE="letter-spacing: 0.05pt">i</FONT>dity
of the Com<FONT STYLE="letter-spacing: 0.05pt">m</FONT>on Stock o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fered hereby will be passed
upon for us by Dickinson Wright PLLC, Fort Lauderdale, FL. Dawson James is being repres<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nted
in connect<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on with this o<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fering by Nelson Mullins
Riley &amp; Scarborough LLP, Raleigh, NC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B><A NAME="a_012"></A>EXPE<FONT STYLE="letter-spacing: -0.25pt">R</FONT>TS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 267.3pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The audited financial statements
incorporated by reference in this prospectus and elsewhere in the r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>gistration s<FONT STYLE="letter-spacing: 0.05pt">t</FONT>atement
have been so incorporated by reference in reliance upon the report of Sadler, Gibb &amp; Associates, LLC, independent regis<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ered
pub<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ic accountants, upon the authority of said firm as experts in account<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng
and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B><A NAME="a_013"></A>WHERE YOU CAN FIND MORE INFORM<FONT STYLE="letter-spacing: -0.6pt">A</FONT>TION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 187.3pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.7pt">W</FONT>e h<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ve
filed a registration statement on Form S-3 with the SEC under the Securit<FONT STYLE="letter-spacing: 0.05pt">i</FONT>es Act of 1933 with
respect to the shar<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s of Common Sto<FONT STYLE="letter-spacing: 0.05pt">c</FONT>k o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fered
by this prospectus supplement. This prosp<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ctus suppl<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ment
<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd the accomp<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nying prospec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>us
are part of the registr<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tion st<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tement but <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he
reg<FONT STYLE="letter-spacing: 0.05pt">i</FONT>stration statement <FONT STYLE="letter-spacing: 0.05pt">i</FONT>ncludes and incorporates
by r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ference addition<FONT STYLE="letter-spacing: 0.05pt">a</FONT>l information and exhib<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ts.
<FONT STYLE="letter-spacing: 0.05pt">T</FONT>his prospectus supplement do<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s not contain all
<FONT STYLE="letter-spacing: 0.05pt">t</FONT>he information set for<FONT STYLE="letter-spacing: 0.05pt">t</FONT>h in the registr<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tion
s<FONT STYLE="letter-spacing: 0.05pt">t</FONT>atement and its exhibits and sch<FONT STYLE="letter-spacing: 0.05pt">e</FONT>dules, por<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ions
of which have b<FONT STYLE="letter-spacing: 0.05pt">e</FONT>en om<FONT STYLE="letter-spacing: 0.05pt">i</FONT>tted <FONT STYLE="letter-spacing: 0.05pt">a</FONT>s
perm<FONT STYLE="letter-spacing: 0.05pt">i</FONT>tted by the rules and regulations of the SEC. For further informa<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ion
about us, we r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>fer you <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o the registration statement
and <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o its exhibits and schedules. Certa<FONT STYLE="letter-spacing: 0.05pt">i</FONT>n information
in the registra<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ion sta<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ement h<FONT STYLE="letter-spacing: 0.05pt">a</FONT>s
been o<FONT STYLE="letter-spacing: 0.05pt">m</FONT>itted from <FONT STYLE="letter-spacing: 0.05pt">t</FONT>his prospe<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tus
suppl<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ment and the a<FONT STYLE="letter-spacing: 0.05pt">c</FONT>companying prospectus in
a<FONT STYLE="letter-spacing: 0.05pt">c</FONT>cordance with the rules of the SEC. <FONT STYLE="letter-spacing: -0.7pt">W</FONT>e file
annua<FONT STYLE="letter-spacing: 0.05pt">l</FONT>, quart<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rly and current reports, proxy st<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tements
<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd other infor<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ation with the SE<FONT STYLE="letter-spacing: 0.05pt">C</FONT>.
The SEC mainta<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ns a webs<FONT STYLE="letter-spacing: 0.05pt">i</FONT>te that contains reports,
proxy and information statements and other information regarding <FONT STYLE="letter-spacing: 0.05pt">c</FONT>ompanies, <FONT STYLE="letter-spacing: 0.05pt">s</FONT>uch
as ours, that file documents ele<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tronically with the S<FONT STYLE="letter-spacing: 0.05pt">E</FONT>C.
The address of that website is http://ww<FONT STYLE="letter-spacing: -0.55pt">w</FONT>.sec.go<FONT STYLE="letter-spacing: -0.55pt">v</FONT>.
The information on the SEC<FONT STYLE="letter-spacing: -0.45pt">&rsquo;</FONT>s website is not part of this prosp<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ctus
suppl<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ment or the accompany<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng prospectus, and
any ref<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rences <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o this website or any other website
are in<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ctive textu<FONT STYLE="letter-spacing: 0.05pt">a</FONT>l references onl<FONT STYLE="letter-spacing: -0.5pt">y</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.7pt">W</FONT>e
also make av<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ilable free of cha<FONT STYLE="letter-spacing: -0.1pt">r</FONT>ge our annual
reports on Form 10-K, qu<FONT STYLE="letter-spacing: 0.05pt">a</FONT>rterly r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ports on Form
10-Q, <FONT STYLE="letter-spacing: 0.05pt">c</FONT>urrent reports on Form 8-K, proxy statements and a<FONT STYLE="letter-spacing: 0.05pt">m</FONT>endments
to those reports, on our website at www.lunaibioworks.com as soon as reasonably pract<FONT STYLE="letter-spacing: 0.05pt">i</FONT>cable
after fil<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng su<FONT STYLE="letter-spacing: 0.05pt">c</FONT>h do<FONT STYLE="letter-spacing: 0.05pt">c</FONT>uments
with the SEC. The information contained on, or that m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>y be accessed through, our websi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>e
is not a part of, and is not incorporated into, this prosp<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ctus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>INCORPOR<FONT STYLE="letter-spacing: -0.6pt">A</FONT>TION
OF CE<FONT STYLE="letter-spacing: -0.3pt">R</FONT><FONT STYLE="letter-spacing: -0.65pt"><A NAME="a_014"></A>T</FONT>AIN INFORM<FONT STYLE="letter-spacing: -0.65pt">A</FONT>TION
BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 150.05pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The S<FONT STYLE="letter-spacing: 0.05pt">E</FONT>C
p<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rmits us <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o &ldquo;<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ncorporate
by r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ference&rdquo; the information cont<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ined
<FONT STYLE="letter-spacing: 0.05pt">i</FONT>n docu<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ents <FONT STYLE="letter-spacing: 0.05pt">w</FONT>e
fi<FONT STYLE="letter-spacing: 0.05pt">l</FONT>e <FONT STYLE="letter-spacing: 0.05pt">w</FONT>ith <FONT STYLE="letter-spacing: 0.05pt">t</FONT>he
S<FONT STYLE="letter-spacing: 0.05pt">E</FONT>C, wh<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ch <FONT STYLE="letter-spacing: 0.05pt">m</FONT>eans
that we <FONT STYLE="letter-spacing: 0.05pt">c</FONT>an d<FONT STYLE="letter-spacing: 0.05pt">i</FONT>sclose important informat<FONT STYLE="letter-spacing: 0.05pt">i</FONT>on
to you by r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ferring you to those documents rath<FONT STYLE="letter-spacing: 0.05pt">e</FONT>r
than by including them in <FONT STYLE="letter-spacing: 0.05pt">t</FONT>his prospectus supplement <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd
<FONT STYLE="letter-spacing: 0.05pt">t</FONT>he accompanying prospectus. Information th<FONT STYLE="letter-spacing: 0.05pt">a</FONT>t
is incorporat<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d by reference is <FONT STYLE="letter-spacing: 0.05pt">c</FONT>onsidered to
be part of this prospectus suppl<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ment and the <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ccompanying
prospectus <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd you should read it with the same care that you r<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ad
th<FONT STYLE="letter-spacing: 0.05pt">i</FONT>s prospec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>us supple<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ent
<FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd the acco<FONT STYLE="letter-spacing: 0.05pt">m</FONT>panying prospec<FONT STYLE="letter-spacing: 0.05pt">t</FONT>us.
L<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ter <FONT STYLE="letter-spacing: 0.05pt">i</FONT>nformation that we f<FONT STYLE="letter-spacing: 0.05pt">i</FONT>le
w<FONT STYLE="letter-spacing: 0.05pt">i</FONT>th the SEC will automatic<FONT STYLE="letter-spacing: 0.05pt">a</FONT>lly upda<FONT STYLE="letter-spacing: 0.05pt">t</FONT>e
and supersede the information that is either contained, or <FONT STYLE="letter-spacing: 0.05pt">i</FONT>ncorporated by refer<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nce,
in this prospectus supplement and the accompanying prospectus, and will be cons<FONT STYLE="letter-spacing: 0.05pt">i</FONT>dered to be
a part of this prospectus supplement and the accompany<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng prospectus from the date those do<FONT STYLE="letter-spacing: 0.05pt">c</FONT>uments
<FONT STYLE="letter-spacing: 0.05pt">a</FONT>re filed. <FONT STYLE="letter-spacing: -0.7pt">W</FONT>e have filed with the SEC, and incorporate
by ref<FONT STYLE="letter-spacing: 0.05pt">e</FONT>rence in this prospe<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tus supplement and
the <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ccompanying prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Annual Report on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001527728/000173112225001316/e6882_10-k.htm">Form 10-K</A> for the year ended June 30, 2025, filed September 29, 2025;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Quarterly Report on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001527728/000173112225001544/e7036_10q.htm">Form 10-Q</A> for the quarter ended September 30, 2025, filed November 14, 2025;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Current Reports on Form 8-K
                                                                                                    (excluding any reports or portions thereof that are deemed to be furnished and not filed) filed on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001527728/000173112225000948/e6687_8k.htm">July
                                                                                                    9, 2025</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001527728/000173112225000971/e6700_8-k.htm">July 14, 2025</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001527728/000173112225001030/e6736_8-k.htm">July
                                                                                                    25, 2025</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001527728/000173112225001076/e6758_8k.htm">August 6,
                                                                                                    2025</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001527728/000173112225001173/e6800_8k.htm">August 26, 2025</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001527728/000173112225001204/e6829_8-k.htm">September
                                                                                                    5, 2025</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001527728/000173112225001297/e6874_8k.htm">September 24,
                                                                                                    2025</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001527728/000173112225001399/e6960_8-k.htm">October 16, 2025</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001527728/000173112225001446/e6985_8-k.htm">October
                                                                                                    30, 2025</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001527728/000173112225001465/e6995_8-k.htm">November 3,
                                                                                                    2025</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001527728/000173112225001495/e7011_8-k.htm">November 6, 2025</A>
                                                                                                    and <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001527728/000173112225001597/e7070_8k.htm">November 25, 2025</A>; and</FONT></P>


</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the description of securities set forth in the section titled &ldquo;<A HREF="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000975/e2119_4-1.htm">Description of Securities</A>&rdquo; in Exhibit 4.6 to our Annual Report on Form 10-K for the fiscal year ended June 30, 2025, and any amendment or report
filed with the SEC for the purpose of updating such description.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.7pt">W</FONT>e also
incorporate by reference all addition<FONT STYLE="letter-spacing: 0.05pt">a</FONT>l docum<FONT STYLE="letter-spacing: 0.05pt">e</FONT>nts
<FONT STYLE="letter-spacing: 0.05pt">t</FONT>hat we file with the Securit<FONT STYLE="letter-spacing: 0.05pt">i</FONT>es <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd
Exchange Com<FONT STYLE="letter-spacing: 0.05pt">m</FONT>ission under the terms of Sections 13(a), 13(c), 14 or 15(d) of the <FONT STYLE="letter-spacing: 0.05pt">E</FONT>xchange
Act <FONT STYLE="letter-spacing: 0.05pt">t</FONT>hat are <FONT STYLE="letter-spacing: 0.05pt">m</FONT>ade after the date of the initial
registration s<FONT STYLE="letter-spacing: 0.05pt">t</FONT>atement but prior to e<FONT STYLE="letter-spacing: -0.1pt">f</FONT>fectiveness
of the reg<FONT STYLE="letter-spacing: 0.05pt">i</FONT>stration statement and after the date of this prospectus supplement but prior to
the termin<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tion of the o<FONT STYLE="letter-spacing: -0.15pt">f</FONT>fering of the securities
covered by this prospe<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tus suppl<FONT STYLE="letter-spacing: 0.05pt">e</FONT>ment and the
<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ccompanying prospe<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tus. <FONT STYLE="letter-spacing: -0.75pt">W</FONT>e
are not, howeve<FONT STYLE="letter-spacing: -0.3pt">r</FONT>, incorporating, in each case, <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ny
documents or information <FONT STYLE="letter-spacing: 0.05pt">t</FONT>hat we are deem<FONT STYLE="letter-spacing: 0.05pt">e</FONT>d to
furnish and not fi<FONT STYLE="letter-spacing: 0.05pt">l</FONT>e in accordance with S<FONT STYLE="letter-spacing: 0.05pt">e</FONT>curities
and Ex<FONT STYLE="letter-spacing: 0.05pt">c</FONT>hange Commission rul<FONT STYLE="letter-spacing: 0.05pt">e</FONT>s.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="letter-spacing: -0.85pt">Y</FONT>ou
may request, and we will provide you with, a copy of these fil<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ngs, at no cost, by c<FONT STYLE="letter-spacing: 0.05pt">a</FONT>lling
us or by wr<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ting <FONT STYLE="letter-spacing: 0.05pt">t</FONT>o us at the following address
and phone number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">If you m<FONT STYLE="letter-spacing: 0.05pt">a</FONT>ke
a request for such <FONT STYLE="letter-spacing: 0.05pt">i</FONT>nformation <FONT STYLE="letter-spacing: 0.05pt">i</FONT>n writing or
by telephone, we will provide you, without cha<FONT STYLE="letter-spacing: -0.1pt">r</FONT>ge, a copy of any or all of the
information incorporated by reference into this prospectus supp<FONT STYLE="letter-spacing: 0.05pt">l</FONT>ement <FONT STYLE="letter-spacing: 0.05pt">a</FONT>nd
the accompany<FONT STYLE="letter-spacing: 0.05pt">i</FONT>ng prospectus (other <FONT STYLE="letter-spacing: 0.05pt">t</FONT>han an
exhibit to <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ny filing unless we have specif<FONT STYLE="letter-spacing: 0.05pt">i</FONT>cally
incorporated that <FONT STYLE="letter-spacing: 0.05pt">e</FONT>xhibit by reference <FONT STYLE="letter-spacing: 0.05pt">i</FONT>nto
the filing)<FONT STYLE="letter-spacing: 1.75pt">.</FONT> Any such request should be directed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt"><B>LUNAI BIOWORKS INC.</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>3400 Cottage Way, Suite G2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center"><B>#32562, Sacramento, CA 95825</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>(424) 222-9301</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 243.55pt 0 3in; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt">You may also access these documents, free of charge on the SEC&rsquo;s
website at www.sec.gov. Our website address <FONT STYLE="letter-spacing: 0.05pt">i</FONT>s www.lunaibioworks.com. Except for any documents
that are incorpora<FONT STYLE="letter-spacing: 0.05pt">t</FONT>ed by reference into this prospectus supplement and the accompanying prospectus
that may be <FONT STYLE="letter-spacing: 0.05pt">a</FONT>ccessed from our websi<FONT STYLE="letter-spacing: 0.05pt">t</FONT>e, the inform<FONT STYLE="letter-spacing: 0.05pt">a</FONT>tion
<FONT STYLE="letter-spacing: 0.05pt">a</FONT>vailable on or through our w<FONT STYLE="letter-spacing: 0.05pt">e</FONT>bsite is not part
of this prospectus supplement or the accompanying prospe<FONT STYLE="letter-spacing: 0.05pt">c</FONT>tus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.45in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;<IMG SRC="image_001.jpg" ALT="" STYLE="height: 52px; width: 147px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;<B>Up to $11,702,826</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Lunai Bioworks, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>December 2, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>$200,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Renovaro Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may from time to time, in one
or more offerings at prices and on terms that we will determine at the time of each offering, sell common stock, warrants, or a combination
of these securities, or units, up to a total offering price of $200,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus describes the
general manner in which our securities may be offered using this prospectus. Each time we offer and sell securities, we will provide you
with a prospectus supplement that will contain specific information about the terms of that offering. Any prospectus supplement may also
add, update, or change information contained in this prospectus. You should carefully read this prospectus and the applicable prospectus
supplement as well as the documents incorporated or deemed to be incorporated by reference in this prospectus before you purchase any
of the securities offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus may not be used
to offer and sell securities unless accompanied by a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Common Stock is listed on
The Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;RENB&rdquo;. On October 29, 2024, the last reported sales price
for our common stock was $0.51 per share. The applicable prospectus supplement will contain information, where applicable, as to any other
listing of the securities on Nasdaq or any other securities market or exchange covered by the prospectus supplement. Prospective purchasers
of our securities are urged to obtain current information as to the market prices of our securities, where applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may offer the securities directly
or through agents or to or through underwriters or dealers. If any agents or underwriters are involved in the sale of the securities their
names, and any applicable purchase price, fee, commission or discount arrangement between or among them, will be set forth, or will be
calculable from the information set forth, in an accompanying prospectus supplement. We can sell the securities through agents, underwriters
or dealers only with delivery of a prospectus supplement describing the method and terms of the offering of such securities. See &ldquo;Plan
of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The aggregate market value of
our outstanding common stock held by non-affiliates was approximately $111.9 million which was calculated based on 120,297,244 shares
of outstanding common stock held by non-affiliates as of October 16, 2024, and a price per share of $0.93, the closing price of our common
stock on October 16, 2024. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public offering
with a value of more than one-third of our public float in any 12-month period, so long as our public float is less than $75,000,000.
As of the date of this prospectus, we have not offered and sold any shares of our common stock pursuant to General Instruction I.B.6 to
Form S-3 during the prior 12 calendar month period that ends on and includes the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Investing in our securities
involves significant risks. We strongly recommend that you read carefully the risks we describe in this prospectus and in any accompanying
prospectus supplement, as well as the risk factors that are incorporated by reference into this prospectus from our filings made with
the Securities and Exchange Commission. See &ldquo;Risk Factors&rdquo; beginning on page 3 of this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">This prospectus is dated November
6, 2024</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#y_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#y_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#y_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#y_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#y_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#y_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;6</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#y_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;7</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#y_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;8</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#y_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;9</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#y_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;12</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#y_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;12</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#y_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;12</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#y_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>You should rely only on the
information contained or incorporated by reference in this prospectus or any prospectus supplement. We have not authorized anyone to provide
you with information different from that contained or incorporated by reference into this prospectus. If any person does provide you with
information that differs from what is contained or incorporated by reference in this prospectus, you should not rely on it. No dealer,
salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus. You should
assume that the information contained in this prospectus or any prospectus supplement is accurate only as of the date on the front of
the document and that any information contained in any document we have incorporated by reference is accurate only as of the date of the
document incorporated by reference, regardless of the time of delivery of this prospectus or any prospectus supplement or any sale of
a security. These documents are not an offer to sell or a solicitation of an offer to buy these securities in any circumstances under
which the offer or solicitation is unlawful.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 26; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="y_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus is part of a registration
statement that we filed with the Securities and Exchange Commission, or SEC, using a &ldquo;shelf&rdquo; registration process. Under this
shelf registration process, we may sell any combination of the securities described in this prospectus in one of more offerings up to
a total dollar amount of proceeds of $200,000,000. This prospectus describes the general manner in which our securities may be offered
by this prospectus. Each time we sell securities, we will provide a prospectus supplement that will contain specific information about
the terms of that offering. The prospectus supplement may also add, update or change information contained in this prospectus or in documents
incorporated by reference in this prospectus. The prospectus supplement that contains specific information about the terms of the securities
being offered may also include a discussion of certain U.S. Federal income tax consequences and any risk factors or other special considerations
applicable to those securities. To the extent that any statement that we make in a prospectus supplement is inconsistent with statements
made in this prospectus or in documents incorporated by reference in this prospectus, you should rely on the information in the prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">You should not assume that the
information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any
date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct
on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement
or any related free writing prospectus is delivered, or securities are sold, on a later date. You should carefully read both this prospectus
and any prospectus supplement together with the additional information described under &ldquo;Where You Can Find More Information&rdquo;
before buying any securities in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The terms &ldquo;Renovaro&rdquo;,
the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; or &ldquo;us,&rdquo; in this prospectus refer to Renovaro Inc. and its
wholly-owned subsidiaries, unless the context suggests otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="y_002"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Some of the statements made under
&ldquo;Prospectus Summary,&rdquo; &ldquo;Use of Proceeds,&rdquo; and elsewhere in this prospectus, as well as the documents incorporated
by reference herein, including in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024, constitute forward-looking statements
within the meaning of The Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements
by terminology such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo; &ldquo;intends,&rdquo; or &ldquo;continue,&rdquo;
or the negative of these terms or other comparable terminology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Forward-looking statements include,
but are not limited to, statements concerning:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 20px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to continue as a going concern and ability
    to raise additional capital;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our continuous incurrence
    of losses as a pre-clinical-stage biotechnology company with no products that have achieved regulatory approval;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to generate revenue if we fail to develop
    marketable product;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our dependence on substantial
    additional financing to support the research, development, licensing, manufacture, and marketing of product candidates and products,
    and the possibility that unforeseen operational costs will arise;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The dilutive effect on
    stockholders&rsquo; ownership interests of the Company raising capital through an equity issuance in connection with future equity
    financing or equity debt agreements;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our dependence on the services
    of experts, including third parties to research and develop product candidates in cooperation with our employees and officers;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The difficulty or impossibility
    of predicting future clinical trial results and regulatory outcomes of our products based upon our pre-clinical or earlier clinical
    trial performance;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The application of heightened
    regulatory and commercial scrutiny to our AI-based technology, gene, cell, and immunotherapy products given their novel nature and
    concomitant potential for actual or perceived safety issues;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to compete
    in rapidly developing fields, and the potential impact to our financial condition, product marketability, and operational capacities
    of a competitor receiving regulatory approval before us, or a competitor developing more advanced or efficacious products;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential delays or total
    failures of third parties, such as universities, non-profits, and clinical research centers, to perform obligations on which our
    product research and development rely;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The impact on our competitive
    position, business operations, and financial condition of implementation of amended healthcare laws and regulations;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The dependence of certain
    of our pipelines on intellectual property licensed from licensors, and the severe adverse impact to our business operations of a
    disruption of one of our licensing relationships;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The potential monetary
    costs of defending our intellectual property rights in a dispute, and the possibility that an intellectual property dispute will
    not be settled in our favor;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The possibility that our
    patents and patent applications, even if unchallenged, will not sufficiently protect or provide exclusive use of our intellectual
    property, which could jeopardize our ability to commercialize our products and dissuade companies from subsequently collaborating
    with us;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 28; Options: NewSection; Value: 3 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 20px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The negative impact to
    our competitive position and the value of our technology of our failure to protect trade secrets through the use of non-disclosure
    and confidentiality agreements, or the unavailability of adequate recourse for breach of such agreements;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fluctuation and volatility
    of the market price of our Common Stock due to its limited public market, and the possibility that these issues will compound and
    strain our stockholders&rsquo; ability to resell their Common Stock;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our significant dependence
    on sophisticated management with highly technical expertise to oversee business operations, and our ability to attract and retain
    qualified personnel to sustain growth;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to adapt to
    future growth by training an expanding employee base and shifting away from reliance on third-party contractors;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The risk of liability arising
    from claims of environmental damage, personal injury, and property damages in connection with our research and development activities,
    including those that involve the use of hazardous materials;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The possibility that enforcement
    actions to suspend or severely restrict our business operations will be brought against the Company for our failure to comply with
    laws or regulations and the potential costs of defending against such actions; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our reliance on adequate
    maintenance of the security and integrity of our information technology systems to effectively operate our business.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Forward-looking statements are
not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on assumptions
and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected
future developments, and other factors they believe to be appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Important factors that could cause
actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include,
among others, those factors referred to in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024, which is incorporated
by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These statements are only current
predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry&rsquo;s actual
results, levels of activity, performance, or achievements to be materially different from those anticipated by the forward-looking statements.
We discuss many of these risks in the documents incorporated by reference herein. You should not rely upon forward-looking statements
as predictions of future events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although we believe that the expectations
reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.
Except as required by law, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new
information, future events or otherwise, after the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 29; Value: 3 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><A NAME="y_003"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>This summary highlights certain
information about us and selected information contained in the prospectus. This summary is not complete and does not contain all of the
information that may be important to you. For a more complete understanding of the Company, we encourage you to read and consider the
more detailed information included or incorporated by reference in this prospectus and our most recent consolidated financial statements
and related notes.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Company Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Inc. operates through two subsidiaries, Renovaro Biosciences and Renovaro
Cube. Renovaro Cube refers to Renovaro Cube Intl. Ltd. and its wholly owned subsidiaries GediCube, B.V. and Grace Systems B.V., which
were acquired on February 13, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Renovaro Biosciences Overview</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Biosciences is a biotechnology company intending, if the necessary funding is obtained, to develop advanced allogeneic cell and gene therapies
to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers,
and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections. As a result of our
acquisition of GEDi Cube Intl on February 13, 2024, we have shifted the Company&rsquo;s primary focus and resources to the development
of the GEDi Cube Intl technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Therapeutic Technologies</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Bioscience aims to train
the immune system to allow a person to better fight diseases through allogeneic cell and/or gene therapy. Our vision is for a world with
healthy longevity, and free from toxic chemotherapy, for those with cancer and other serious diseases. Renovaro Biosciences will seek
to leverage general principles and advances in the knowledge of the immune response to engineer cells with enhanced attributes to promote
the recognition and elimination of disease cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Allogeneic Cell Therapy </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The strategic benefit of the allogeneic
cell therapy technologies is to potentially allow for the manufacture of large, &ldquo;off-the-shelf&rdquo; banks of therapeutic cells
that are readily available on demand by healthcare professionals, to potentially decrease the time between diagnosis and treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In certain treatments (e.g., HIV
and cancer), cells taken from healthy donors are engineered to introduce signaling molecules that are designed to enhance the ability
of specific immune cells to recognize diseased cells, and to help recruit other cells that will destroy cancer or virus infected cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Gene Therapy</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Biosciences may also
seek to explore various approaches for gene therapy design elements to potentially eliminate virus-infected or cancer cells by the modulation
of the patient&rsquo;s immune system. Upon injecting into the patients, these genetically engineered allogeneic cells have little to no
risk of passing those modifications to the patient since they are terminally differentiated with locked functionality to activate the
host immune system. Gene modified allogeneic cells are expected to be rejected naturally once they activate the patient&rsquo;s immune
system therefore will have a very short survival time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Options: NewSection -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Renovaro Biosciences Focus Areas:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><U>Oncology:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><U>RENB-DC11: Genetically modified
Allogeneic Dendritic Cell Therapeutic Vaccine as Potential Product for Long-term Remission of Solid Tumors; specifically Pancreatic tumors</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Allogeneic Cell Therapy Platform
&ndash; Completed pre-IND, IND-enabling phase.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Based
on learnings from our internal research, literature reviews of ongoing clinical development for solid tumors, and recent advances in immune
modulation, we have designed an innovative therapeutic vaccination platform that could potentially be used to induce life-long remission
from some of the deadliest solid tumors such as pancreatic, liver, triple negative breast and head &amp; neck cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The platform
may one day enable broad immune enhancements that are combined with cancer specific antigens that could be applicable to a wide range
of solid tumors. This approach allows us to quickly adapt our approach to any patient solid tumor using the same banked allogenic drug
substance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><U>RENB-DC20: Genetically modified Allogeneic Dendritic
Cell Therapeutic Vaccine as Potential Treatment Product for Long-term Remission of Triple Negative Breast Cancer</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Triple Negative Breast Cancer
(TNBC) is a subtype of breast cancer that is negative for estrogens receptor (ER) negative, progesterone receptor (PR) negative and human
epidermal growth factor receptor 2 (HER2). TNBC is characterized by its unique molecular profile, aggressive nature, and distinct metastatic
patterns that lack targeted therapies. TNBC is well known for its aggressive behavior and is characterized by onset at a younger age,
high mean tumor size, and higher-grade tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based upon our internal research,
literature reviews of ongoing clinical development for solid tumors, and recent advances in immune modulation, we believe we may have
the ability to design an innovative therapeutic vaccination platform that could potentially be used to treat some of the deadliest and
hard-to-treat solid tumors that include triple negative breast cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><U>Infectious Diseases:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><U>RENB-HV12: Genetically Modified
Allogeneic Dendritic Cell Therapeutic Vaccine as Potential Treatment Product for Long-term Remission of HIV; A Chronic Infectious Disease</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The oncology therapeutic vaccine
technology could potentially be adapted to target infectious disease antigens and be a viable therapeutic approach in difficult to treat
chronic infectious diseases. As described above, the engineered allogenic dendritic cell drug substance is thought to be able to be loaded
with various cancer antigens for specific solid tumors but could or may be loaded with infectious disease antigens to elicit a more robust
immune response to viruses and other difficult to treat infections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Renovaro Cube Overview</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube is an AI-driven
healthcare technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has developed a
proprietary AI platform that analyzes genetics using Explainable AI (as defined below) to provide earlier and more accurate cancer diagnosis.
This platform uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. This approach
is combined with differential molecular capabilities that are designed to identify, differentiate and pinpoint the exact source. Renovaro
Cube&rsquo;s process also involves the mining of biomarker panels, which are integrated into a machine learning library referred to as
&ldquo;RenovaroCube&rdquo; to further enhance diagnosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube also aims to utilize
its proprietary AI platform in the development of commercial products to support clinical, research and pharmaceutical organizations that
are trying to improve patient care through precision diagnosis, prediction of success of therapy, new drug discovery, treatment protocols
or clinical trials. Specifically, Renovaro Cube is focused on developing products and services aimed at (i) early cancer characterization,
(ii) personalized treatment selection, (iii) prediction and tracking response to therapies, (iv) recurrence detection and efficacy monitoring,
and (v) ultimately, drug discovery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube was initially incorporated
as Grace Systems B.V. (&ldquo;Grace Systems&rdquo;) in 2013 under the laws of the Netherlands to develop unique data mining algorithms
to enable banking, finance and government entities to extract business insights from data. Grace Systems began applying its algorithms
to biological data in 2018 to uncover cancer-associated patterns. Beginning in 2018, Grace Systems pivoted its platform to focus only
on healthcare. Renovaro Cube has focused on developing its AI technology for early cancer detection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube has now focused
on commercialization of its AI technology. Renovaro Cube believes that it has developed a unique approach to the early detection and diagnosis
of cancer and its recurrence and, in time, other rare diseases through the systematic analysis of data using AI technologies, data mining
procedures and algorithms for health technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Renovaro Cube&rsquo;s technology
has been trained on complex heterogeneous cancer data and appears to find patterns associated with cancer in public and private data resources.
With the help of Renovaro Cube&rsquo;s algorithms, discovered patterns may be translated into biomarkers that can be used in a clinical
setting to target various aspects of cancer diagnosis and treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28pt"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><U>Renovaro Cube&rsquo;s Strategy</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Renovaro Cube&rsquo;s product development
focuses on four core areas:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Early Detection. </B>Multi-cancer
    early detection (&ldquo;MCED&rdquo;) blood tests are advanced diagnostic tools that analyze cell-derived molecules present in the
    bloodstream. These tests specifically look for abnormal genetic, epigenetic or proteomic patterns of these cell-derived molecules,
    which can indicate the presence of cancer cells. By examining the molecules shed from various cells, including cancer cells, MCED
    tests aim to detect cancer at an early stage. This approach holds promise for improving cancer detection and potentially saving lives.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recurrence of cancer</B>.
    A recurrence refers to the return of cancer after a period of remission. A cancer recurrence happens because, in spite of the efforts
    to kill the cancer, some cells may remain, which grow and eventually cause symptoms. In rare instances, a patient may develop a new
    cancer that&rsquo;s completely unrelated to the originally diagnosed cancer, which is referred to as a second primary cancer. An
    early warning system could help to identify a recurrence as early as possible, thereby helping to accelerate any treatment and diagnosis.
    The different types of recurrence include:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Local recurrence,</B>&nbsp;meaning
    that the cancer has returned in the same place it first started;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regional recurrence</B>,
    meaning that the cancer has returned to the lymph nodes near the place it first started; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Distant recurrence</B>,
    meaning the cancer has returned in another part of the body.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Response to treatment.
    </B>At Renovaro Cube we aim to develop a new array of diagnostic products that can accurately identify patients that are going to
    respond or fail to a certain drug. In highly toxic therapies it will not only increase survival, but it will also reduce unnecessary
    exposure to chemotherapy. Furthermore, the costs for cancer drugs are usually very high. Providing the right therapy to the right
    patient will therefore significantly reduce the costs of medicine in cancer. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical trials</B>.
    Clinical trials involve a type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
    People volunteer to take part in clinical trials to test medical interventions including drugs, cells and other biological products,
    surgical procedures, radiological procedures, devices, behavioral treatments and preventive care. Clinical trials are carefully designed,
    reviewed and completed, and need to be approved before they can start.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are incorporated under the
laws of Delaware. Our principal executive offices are located at 2080 Century Park East, Suite 906, Los Angeles, California 90067. Our
telephone number is (305) 918-1980. Our website address is <I>www.renovarogroup.com</I>. The references to our website in this prospectus
are inactive textual references only. The information on our website is neither incorporated by reference into this prospectus nor intended
to be used in connection with this offering. We have included our website address in this prospectus as an inactive textual reference
only and not as an active hyperlink.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><A NAME="y_004"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Investing in our securities involves
risks. You should carefully consider the risks, uncertainties and other factors described in our most recent Annual Report on Form 10-K
and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and in other documents which are incorporated by reference
into this prospectus, as well as the risk factors and other information contained in or incorporated by reference into any accompanying
prospectus supplement before investing in any of our securities. Our business, financial condition, results of operations, cash flows
or prospects could be materially and adversely affected by any of these risks. The risks and uncertainties described in the documents
incorporated by reference herein are not the only risks and uncertainties that you may face.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For more information about our
SEC filings, please see the sections entitled &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Documents
by Reference&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="y_005"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We will retain broad discretion
over the use of the net proceeds from the sale of the securities offered hereby. Unless otherwise specified in a prospectus supplement
accompanying this prospectus, the net proceeds from the sale by us of the securities to which this prospectus relates will be used for
working capital and general corporate purposes. Our expected use of proceeds from the sale of the securities offered hereby represents
our current intentions based on our present plans and business condition. As of the date of this prospectus, we cannot predict with certainty
all of the particular uses for the proceeds to be received from the sale of the securities offered hereby or the amounts that we will
actually spend on the uses set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">When we offer and sell the securities
to which this prospectus relates, the prospectus supplement related to such offering will set forth our intended use of the proceeds,
if any, received from the sale of such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="y_006"></A>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following description of our
capital stock, together with any additional information we include in any applicable prospectus supplement or any related free writing
prospectus, summarizes the material terms and provisions of our common stock that we may offer under this prospectus. For the complete
terms of our common stock, please refer to our articles of incorporation and our bylaws that are incorporated by reference into the registration
statement of which this prospectus is a part. The summary below and that contained in any applicable prospectus supplement or any related
free writing prospectus are qualified in their entirety by reference to our articles of incorporation and our bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are authorized to issue 350,000,000 shares of common stock, $0.0001 par
value per share. As of October 27, 2024, there were 161,717,342 shares of common stock issued and outstanding. The outstanding shares
of common stock are validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Voting</I> -- Each outstanding
share of Common Stock is entitled to one vote on all matters submitted to a vote of stockholders. There are no cumulative voting rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Dividends</I> -- Each stockholder
is entitled to receive the dividends as may be declared by our board of directors out of funds legally available for dividends. Our board
of directors is not obligated to declare a dividend. Any future dividends will be subject to the discretion of our board of directors
and will depend upon, among other things, future earnings, the operating and financial condition of our Company, its capital requirements,
general business conditions and other pertinent factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Liquidation Rights</I> -- Each
stockholder is entitled in the event of liquidation, to share pro rata in any distribution of our assets after payment of liabilities,
subject to the rights and preferences of the holders of any outstanding shares of any series of our preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Other Matters</I> -- Holders
of our common stock have no conversion, preemptive or other subscription rights, and there are no redemption rights or sinking fund provisions
with respect to the common stock. All of the issued and outstanding shares of common stock on the date of this report are validly issued,
fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The transfer agent for our common
stock is Securities Transfer Corporation. The transfer agent&rsquo;s address is 2901 N. Dallas Parkway, Suite 380, Plano, TX 75093.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Common Stock is listed on
the Nasdaq Capital Market under the symbol &ldquo;RENB&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="y_007"></A>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may issue warrants for the
purchase of common stock. Warrants may be issued independently or together with any common stock and may be attached to or separate from
any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between a warrant
agent specified in the agreement and us. The warrant agent will act solely as our agent in connection with the warrants of that series
and will not assume any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants. This summary
of some provisions of the securities warrants is not complete. You should refer to the securities warrant agreement, including the forms
of securities warrant certificate representing the securities warrants, relating to the specific securities warrants being offered for
the complete terms of the securities warrant agreement and the securities warrants. The securities warrant agreement, together with the
terms of the securities warrant certificate and securities warrants, will be filed with the SEC in connection with the offering of the
specific warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The applicable prospectus supplement
will describe the following terms, where applicable, of the warrants in respect of which this prospectus is being delivered:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the title of the warrants;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the aggregate number of
    the warrants;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the price or prices at
    which the warrants will be issued;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the designation, amount
    and terms of the offered securities purchasable upon exercise of the warrants;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if applicable, the date
    on and after which the warrants and the offered securities purchasable upon exercise of the warrants will be separately transferable;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of the securities
    purchasable upon exercise of such warrants and the procedures and conditions relating to the exercise of such warrants;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any provisions for adjustment
    of the number or amount of securities receivable upon exercise of the warrants or the exercise price of the warrants;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the price or prices at
    which and currency or currencies in which the offered securities purchasable upon exercise of the warrants may be purchased;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which the right
    to exercise the warrants shall commence and the date on which the right shall expire;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the minimum or maximum
    amount of the warrants that may be exercised at any one time;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information with respect
    to book-entry procedures, if any;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if appropriate, a discussion
    of Federal income tax consequences; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other material terms
    of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Warrants for the purchase of common
stock will be offered and exercisable for U.S. dollars only. Warrants will be issued in registered form only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon receipt of payment and the
warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated
in the applicable prospectus supplement, we will, as soon as practicable, forward the purchased securities. If less than all of the warrants
represented by the warrant certificate are exercised, a new warrant certificate will be issued for the remaining warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Prior to the exercise of any warrants
to purchase common stock, holders of the warrants will not have any of the rights of holders of the common stock purchasable upon exercise,
including in the case of securities warrants for the purchase of common stock, the right to vote or to receive any payments of dividends
on the common stock purchasable upon exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="y_008"></A>DESCRIPTION OF UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As specified in the applicable
prospectus supplement, we may issue units consisting of shares of common stock or warrants or any combination of such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The applicable prospectus supplement
will specify the following terms of any units in respect of which this prospectus is being delivered:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of the units
    and of any of the common stock and warrants comprising the units, including whether and under what circumstances the securities comprising
    the units may be traded separately;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a description of the terms
    of any unit agreement governing the units; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a description of the provisions
    for the payment, settlement, transfer or exchange of the units.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><A NAME="y_009"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may sell the securities offered
through this prospectus (i) to or through underwriters or dealers, (ii) directly to purchasers, including our affiliates, (iii) through
agents, or (iv) through a combination of any these methods. The securities may be distributed at a fixed price or prices, which may be
changed, market prices prevailing at the time of sale, prices related to the prevailing market prices or negotiated prices. The prospectus
supplement will include the following information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of the offering;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the names of any underwriters or agents;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    name or names of any managing underwriter or underwriters;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    purchase price of the securities;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    over-allotment options under which underwriters may purchase additional securities from us;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    net proceeds from the sale of the securities;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delayed delivery arrangements;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    underwriting discounts, commissions and other items constituting underwriters&rsquo; compensation;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    initial public offering price;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    discounts or concessions allowed or reallowed or paid to dealers;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    commissions paid to agents; and</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    securities exchange or market on which the securities may be listed. </FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<B>Sale Through Underwriters or Dealers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Only underwriters named in the
prospectus supplement are underwriters of the securities offered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If underwriters are used in the
sale, the underwriters will acquire the securities for their own account, including through underwriting, purchase, security lending or
repurchase agreements with us. The underwriters may resell the securities from time to time in one or more transactions, including negotiated
transactions. Underwriters may sell the securities in order to facilitate transactions in any of our other securities (described in this
prospectus or otherwise), including other public or private transactions and short sales. Underwriters may offer securities to the public
either through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters.
Unless otherwise indicated in the prospectus supplement, the obligations of the underwriters to purchase the securities will be subject
to certain conditions, and the underwriters will be obligated to purchase all the offered securities if they purchase any of them. The
underwriters may change from time to time any initial public offering price and any discounts or concessions allowed or reallowed or paid
to dealers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If dealers are used in the sale
of securities offered through this prospectus, we will sell the securities to them as principals. They may then resell those securities
to the public at varying prices determined by the dealers at the time of resale. The prospectus supplement will include the names of the
dealers and the terms of the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Direct Sales and Sales Through Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may sell the securities offered
through this prospectus directly. In this case, no underwriters or agents would be involved. Such securities may also be sold through
agents designated from time to time. The prospectus supplement will name any agent involved in the offer or sale of the offered securities
and will describe any commissions payable to the agent. Unless otherwise indicated in the prospectus supplement, any agent will agree
to use its reasonable best efforts to solicit purchases for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may sell the securities directly
to institutional investors or others who may be deemed to be underwriters within the meaning of the Securities Act of 1933 with respect
to any sale of those securities. The terms of any such sales will be described in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Delayed Delivery Contracts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the prospectus supplement indicates,
we may authorize agents, underwriters or dealers to solicit offers from certain types of institutions to purchase securities at the public
offering price under delayed delivery contracts. These contracts would provide for payment and delivery on a specified date in the future.
The contracts would be subject only to those conditions described in the prospectus supplement. The applicable prospectus supplement will
describe the commission payable for solicitation of those contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Continuous Offering Program</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Without limiting the generality
of the foregoing, we may enter into a continuous offering program equity distribution agreement with a broker-dealer, under which we may
offer and sell shares of our common stock from time to time through a broker-dealer as our sales agent. If we enter into such a program,
sales of the shares of common stock, if any, will be made by means of ordinary brokers&rsquo; transactions on the Nasdaq at market prices,
block transactions and such other transactions as agreed upon by us and the broker-dealer. Under the terms of such a program, we also
may sell shares of common stock to the broker-dealer, as principal for its own account at a price agreed upon at the time of sale. If
we sell shares of common stock to such broker-dealer as principal, we will enter into a separate terms agreement with such broker-dealer,
and we will describe this agreement in a separate prospectus supplement or pricing supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Market Making, Stabilization and Other Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Unless the applicable prospectus
supplement states otherwise, other than our common stock all securities we offer under this prospectus will be a new issue and will have
no established trading market. We may elect to list offered securities on an exchange or in the over-the-counter market. Any underwriters
that we use in the sale of offered securities may make a market in such securities, but may discontinue such market making at any time
without notice. Therefore, we cannot assure you that the securities will have a liquid trading market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any underwriter may also engage
in stabilizing transactions, syndicate covering transactions and penalty bids in accordance with Rule 104 under the Securities Exchange
Act of 1934 (the &ldquo;Exchange Act&rdquo;). Stabilizing transactions involve bids to purchase the underlying security in the open market
for the purpose of pegging, fixing or maintaining the price of the securities. Syndicate covering transactions involve purchases of the
securities in the open market after the distribution has been completed in order to cover syndicate short positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Penalty bids permit the underwriters
to reclaim a selling concession from a syndicate member when the securities originally sold by the syndicate member are purchased in a
syndicate covering transaction to cover syndicate short positions. Stabilizing transactions, syndicate covering transactions and penalty
bids may cause the price of the securities to be higher than it would be in the absence of the transactions. The underwriters may, if
they commence these transactions, discontinue them at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>General Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Agents, underwriters, and dealers
may be entitled, under agreements entered into with us, to indemnification by us against certain liabilities, including liabilities under
the Securities Act of 1933. Our agents, underwriters, and dealers, or their affiliates, may be customers of, engage in transactions with
or perform services for us, in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to General Instruction
I.B.6 of Form S-3, in no event will we sell securities in a public offering with a value exceeding more than one-third of our public float
in any 12-calendar month period so long as our public float remains below $75,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="y_010"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The validity of the issuance of
the securities offered by this prospectus will be passed upon for us by K&amp;L Gates LLP, Miami, Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="y_011"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The consolidated financial statements
of Renovaro Inc. as of June 30, 2024 and 2023, and for each of the years then ended, incorporated in this prospectus by reference and
included in our Annual Report on Form 10-K for the year ended June 30, 2024 have been audited by Sadler, Gibb &amp; Associates LLC, an
independent registered public accounting firm. Such consolidated financial statements are incorporated by reference in reliance upon the
report of such firm given their authority as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="y_012"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have filed our registration
statement on Form S-3 with the SEC under the Securities Act of 1933, as may be amended. We also file annual, quarterly and current reports,
proxy statements and other information with the SEC. Our SEC filings are also available to the public at the SEC&rsquo;s web site at www.sec.gov.
These documents may also be accessed on our web site at <I>www.renovarogroup.com</I>. Information contained on our web site is not incorporated
by reference into this prospectus and you should not consider information contained on our web site to be part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus and any prospectus
supplement are part of a registration statement filed with the SEC and do not contain all of the information in the registration statement.
The full registration statement may be obtained from the SEC or us as indicated above. Other documents establishing the terms of the offered
securities are filed as exhibits to the registration statement or will be filed through an amendment to our registration statement on
Form S-3 or under cover of a Current Report on Form 8-K and incorporated into this prospectus by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><A NAME="y_013"></A>INCORPORATION OF CERTAIN DOCUMENTS
BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The SEC allows us to &ldquo;incorporate
by reference&rdquo; into this prospectus the information we file with it, which means that we can disclose important information to you
by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Any statement
contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified
or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document
that is deemed to be incorporated by reference into this document modifies or supersedes the statement. We incorporate by reference in
this prospectus the following information (other than, in each case, documents or information deemed to have been furnished and not filed
in accordance with SEC rules):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our Annual Report on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001527728/000173112224001578/e5986_10-k.htm">Form 10-K</A> for the fiscal year ended June 30, 2024, which were filed with the SEC on October 10, 2024 and the amendment thereto on <A HREF="http://www.sec.gov/Archives/edgar/data/0001527728/000173112224001664/e6062_10ka.htm">Form 10-K/A</A> for the fiscal year ended June 30, 2024, filed on October 28, 2024;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our Current Report on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001527728/000173112224001606/e6034_8-k.htm">Form 8-K</A> filed with the SEC on October 16, 2024 and the amendment thereto on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001527728/000173112224001672/e6067_8-ka.htm">Form 8-K/A</A> filed on October 29, 2024;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the description of our common stock contained in <A HREF="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000975/e2119_4-1.htm">Exhibit 4.1</A> of our Annual Report on Form 10-K for the year ended June 30, 2020, filed with the SEC on September 23, 2020, which updated the description contained in our Registration Statement on Form 8-A (File No. 001-38758); and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">all reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this prospectus and prior to the termination of this offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We also incorporate by reference
any future filings (other than information furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that
are related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act, including those made after the date of the initial filing of the registration statement of which this
prospectus is a part and prior to effectiveness of such registration statement, until we file a post-effective amendment that indicates
the termination of the offering of the securities made by this prospectus and will become a part of this prospectus from the date that
such documents are filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus.
Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously
filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed
document modify or replace such earlier statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
information furnished under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits, is not incorporated
by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information about us contained
in this prospectus should be read together with the information in the documents incorporated by reference. You may request a copy of
any or all of these filings, at no cost, by writing to, or calling us, at: Renovaro Inc., 2080 Century Park East, Suite 906, Los Angeles,
CA 90067, Attention: Chief Executive Officer, telephone number (305) 918-1980.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>$200,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>RENOVARO INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>November 6, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  T ),# 2(  A$! Q$!_\0
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MN?+\^4)NQC.,]>H_.KL$\5S;QW$$BR0RJ'1T.0RD9!!],5Y?\8K7PO<R:/\
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M,YZ\UQ?AJUCT;XXI8V19((KR:)5SGY-K<>]>I?"O_DGUA_OR_P#HQJ\ST_\
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? **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
